SEC Info - Syneos Health, Inc. - ‘10-Q’ for 3/31/21

SEC Info℠

Home

Help

Please Sign In

Syneos Health, Inc. – ‘10-Q’ for 3/31/21

On: Wednesday, 4/28/21, at 5:42pm ET · As of: 4/29/21 · For: 3/31/21 · Accession #: 1564590-21-21455 · File #: 1-36730

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 4/29/21  Syneos Health, Inc.               10-Q        3/31/21   84:9M                                     ActiveDisclosure/FA

Quarterly Report — Form 10-Q
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-Q        Quarterly Report                                    HTML    831K 
 2: EX-31.1     EX-31.1 Section 302 CEO Certification               HTML     27K 
 3: EX-31.2     EX-31.2 Section 302 CFO Certification               HTML     27K 
 4: EX-32.1     EX-32.1 Section 906 CEO Certification               HTML     26K 
 5: EX-32.2     EX-32.2 Section 906 CFO Certification               HTML     25K 
12: R1          Cover Page                                          HTML     76K 
13: R2          Condensed Consolidated Statements of Income         HTML     98K 
                (Unaudited)                                                      
14: R3          Condensed Consolidated Statements of Comprehensive  HTML     41K 
                Income (Loss) (Unaudited)                                        
15: R4          Condensed Consolidated Statements of Comprehensive  HTML     29K 
                Income (Loss) (Unaudited) (Parenthetical)                        
16: R5          Condensed Consolidated Balance Sheets (Unaudited)   HTML    115K 
17: R6          Condensed Consolidated Balance Sheets (Unaudited)   HTML     41K 
                (Parenthetical)                                                  
18: R7          Condensed Consolidated Statements of Cash Flows     HTML    111K 
                (Unaudited)                                                      
19: R8          Condensed Consolidated Statements of Shareholders'  HTML     74K 
                Equity (Unaudited)                                               
20: R9          Basis of Presentation and Changes in Significant    HTML     30K 
                Accounting Policies                                              
21: R10         Financial Statement Details                         HTML    208K 
22: R11         Business Combinations                               HTML     29K 
23: R12         Long-Term Debt Obligations                          HTML     94K 
24: R13         Derivatives                                         HTML     44K 
25: R14         Fair Value Measurements                             HTML    226K 
26: R15         Restructuring and Other Costs                       HTML     71K 
27: R16         Shareholders' Equity                                HTML     63K 
28: R17         Earnings Per Share                                  HTML     66K 
29: R18         Income Taxes                                        HTML     31K 
30: R19         Revenue from Contracts with Customers               HTML     32K 
31: R20         Segment Information                                 HTML    115K 
32: R21         Operations by Geographic Location                   HTML     74K 
33: R22         Concentration of Credit Risk                        HTML     27K 
34: R23         Related-Party Transactions                          HTML     27K 
35: R24         Commitments and Contingencies                       HTML     33K 
36: R25         Basis of Presentation and Changes in Significant    HTML     35K 
                Accounting Policies (Policies)                                   
37: R26         Financial Statement Details (Tables)                HTML    216K 
38: R27         Long-Term Debt Obligations (Tables)                 HTML     91K 
39: R28         Derivatives (Tables)                                HTML     41K 
40: R29         Fair Value Measurements (Tables)                    HTML    226K 
41: R30         Restructuring and Other Costs (Tables)              HTML     69K 
42: R31         Shareholders' Equity (Tables)                       HTML     61K 
43: R32         Earnings Per Share (Tables)                         HTML     64K 
44: R33         Segment Information (Tables)                        HTML    109K 
45: R34         Operations by Geographic Location (Tables)          HTML     77K 
46: R35         Basis of Presentation and Changes in Significant    HTML     25K 
                Accounting Policies - Narrative (Details)                        
47: R36         Financial Statement Details - Schedule Of Cash      HTML     29K 
                Pool Position (Details)                                          
48: R37         Financial Statement Details - Accounts Receivable   HTML     34K 
                and Unbilled Services, net (Details)                             
49: R38         Financial Statement Details - Narrative (Details)   HTML     27K 
50: R39         Financial Statement Details - Schedule of Goodwill  HTML     45K 
                (Details)                                                        
51: R40         Financial Statement Details - Accumulated Other     HTML     41K 
                Comprehensive Loss, Net of Taxes (Details)                       
52: R41         Financial Statement Details - Tax Effects           HTML     51K 
                Allocated to Each Component of Other Comprehensive               
                (Loss) Income (Details)                                          
53: R42         Financial Statement Details - Other Income, Net     HTML     32K 
                (Details)                                                        
54: R43         Business Combinations - Narrative (Details)         HTML     49K 
55: R44         Long-Term Debt Obligations - Schedule of Debt       HTML     50K 
                Obligations (Details)                                            
56: R45         Long-Term Debt Obligations - Narrative (Details)    HTML     65K 
57: R46         Long-Term Debt Obligations - Accounts Receivable    HTML     46K 
                Financing Agreement (Details)                                    
58: R47         Long-Term Debt Obligations - Contractual            HTML     42K 
                Maturities of Debt Obligations (Details)                         
59: R48         Derivatives - Narrative (Details)                   HTML     38K 
60: R49         Derivatives - Interest Rate Swaps Designated as     HTML     38K 
                Hedging Instruments on Consolidated Balance Sheets               
                (Details)                                                        
61: R50         Fair Value Measurements - Schedule of Assets and    HTML     53K 
                Liabilities Measured at Fair Value on a Recurring                
                Basis (Details)                                                  
62: R51         Fair Value Measurements - Schedule of Assets and    HTML     32K 
                Liabilities Measured at Fair Value on a Recurring                
                Basis (Parenthetical) (Details)                                  
63: R52         Fair Value Measurements - Reconciliation of         HTML     33K 
                Changes in the Carrying Amount of Contingent                     
                Consideration (Details)                                          
64: R53         Fair Value Measurements - Narrative (Details)       HTML     45K 
65: R54         Fair Value Measurements - Schedule of Estimated     HTML     46K 
                Fair Value (Details)                                             
66: R55         Restructuring and Other Costs - Schedule of         HTML     33K 
                Restructuring and Related Costs (Details)                        
67: R56         Restructuring and Other Costs - Liabilities         HTML     38K 
                Associated with Restructuring and Other Costs                    
                (Details)                                                        
68: R57         Shareholders' Equity - Shares of Common Stock       HTML     31K 
                Outstanding (Details)                                            
69: R58         Shareholders' Equity - Narrative (Details)          HTML     40K 
70: R59         Shareholders' Equity - Repurchase Activity          HTML     31K 
                (Details)                                                        
71: R60         Earnings Per Share - Schedule of Earnings Per       HTML     57K 
                Share, Basic and Diluted (Details)                               
72: R61         Earnings Per Share - Narrative (Details)            HTML     25K 
73: R62         Income Taxes - Narrative (Details)                  HTML     45K 
74: R63         Revenue from Contracts with Customers - Narrative   HTML     35K 
                (Details)                                                        
75: R64         Segment Information (Details)                       HTML     61K 
76: R65         Operations by Geographic Location - Total Revenue   HTML     45K 
                by Geographic Area (Details)                                     
77: R66         Operations by Geographic Location - Long-Lived      HTML     37K 
                Assets by Geographic Area (Details)                              
78: R67         Concentration of Credit Risk - Narrative (Details)  HTML     31K 
79: R68         Related-Party Transactions - Narrative (Details)    HTML     31K 
80: R69         Commitments and Contingencies - Narrative           HTML     37K 
                (Details)                                                        
82: XML         IDEA XML File -- Filing Summary                      XML    154K 
11: XML         XBRL Instance -- synh-10q_20210331_htm               XML   2.31M 
81: EXCEL       IDEA Workbook of Financial Reports                  XLSX     90K 
 7: EX-101.CAL  XBRL Calculations -- synh-20210331_cal               XML    170K 
 8: EX-101.DEF  XBRL Definitions -- synh-20210331_def                XML    535K 
 9: EX-101.LAB  XBRL Labels -- synh-20210331_lab                     XML   1.15M 
10: EX-101.PRE  XBRL Presentations -- synh-20210331_pre              XML    915K 
 6: EX-101.SCH  XBRL Schema -- synh-20210331                         XSD    156K 
83: JSON        XBRL Instance as JSON Data -- MetaLinks              369±   564K 
84: ZIP         XBRL Zipped Folder -- 0001564590-21-021455-xbrl      Zip    178K

‘10-Q’ — Quarterly Report
Document Table of Contents

Page	(sequential)	(alphabetic)	↑Top
		Alternative Formats (Word, et al.) Condensed Consolidated Balance Sheets as of March 31, 2021 and December 31, 2020 (unaudited) Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2021 and 2020 (unaudited) Condensed Consolidated Statements of Comprehensive Income (Loss) for the three months ended March 31, 2021 and 2020 (unaudited) Condensed Consolidated Statements of Income for the three months ended March 31, 2021 and 2020 (unaudited) Condensed Consolidated Statements of Shareholders' Equity for the three months ended March 31, 2021 and 2020 (unaudited) Controls and Procedures Exhibits Financial Information Financial Statements Legal Proceedings Management's Discussion and Analysis of Financial Condition and Results of Operations Notes to Condensed Consolidated Financial Statements (unaudited) Other Information Part I -- Financial Information Part Ii -- Other Information Quantitative and Qualitative Disclosures About Market Risk Risk Factors Signature Table of Contents Unregistered Sales of Equity Securities, Use of Proceeds and Issuer Purchases of Equity Securities
1	1st Page – Filing Submission
"	Table of Contents
"	Part I -- Financial Information
"	Financial Statements
"	Condensed Consolidated Statements of Income for the three months ended March 31, 2021 and 2020 (unaudited)
"	Condensed Consolidated Statements of Comprehensive Income (Loss) for the three months ended March 31, 2021 and 2020 (unaudited)
"	Condensed Consolidated Balance Sheets as of March 31, 2021 and December 31, 2020 (unaudited)
"	Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2021 and 2020 (unaudited)
"	Condensed Consolidated Statements of Shareholders' Equity for the three months ended March 31, 2021 and 2020 (unaudited)
"	Notes to Condensed Consolidated Financial Statements (unaudited)
"	Management's Discussion and Analysis of Financial Condition and Results of Operations
"	Quantitative and Qualitative Disclosures About Market Risk
"	Controls and Procedures
"	Part Ii -- Other Information
"	Legal Proceedings
"	Risk Factors
"	Unregistered Sales of Equity Securities, Use of Proceeds and Issuer Purchases of Equity Securities
"	Exhibits
"	Signature

This is an HTML Document rendered as filed. [ Alternative Formats ]

iX: C: C: C: C: C: C:

i false i Q1 i 0001610950 i --12-31 i 2021 i i i us-gaap:AccountingStandardsUpdate201613Member i us-gaap:AccountingStandardsUpdate201613Member i us-gaap:AccountingStandardsUpdate201613Member i us-gaap:AccountingStandardsUpdate201613Member 0001610950 2021-01-01 2021-03-31 xbrli:shares 0001610950 2021-04-26 iso4217:USD 0001610950 2020-01-01 2020-03-31 iso4217:USD xbrli:shares 0001610950 2021-03-31 0001610950 2020-12-31 0001610950 2019-12-31 0001610950 2020-03-31 0001610950 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember 2019-12-31 0001610950 us-gaap:CommonStockMember 2020-12-31 0001610950 us-gaap:CommonStockMember 2019-12-31 0001610950 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001610950 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001610950 us-gaap:CommonStockMember 2021-03-31 0001610950 us-gaap:CommonStockMember 2020-03-31 0001610950 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001610950 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001610950 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001610950 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001610950 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001610950 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001610950 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001610950 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001610950 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-03-31 0001610950 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-03-31 0001610950 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-03-31 0001610950 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-31 0001610950 us-gaap:RetainedEarningsMember 2020-12-31 0001610950 us-gaap:RetainedEarningsMember 2019-12-31 0001610950 us-gaap:RetainedEarningsMember srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember 2019-12-31 0001610950 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001610950 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001610950 us-gaap:RetainedEarningsMember 2021-03-31 0001610950 us-gaap:RetainedEarningsMember 2020-03-31 synh:Segment 0001610950 synh:ClinicalSolutionsSegmentMember 2020-12-31 0001610950 synh:CommercialSolutionsSegmentMember 2020-12-31 0001610950 synh:ClinicalSolutionsSegmentMember 2021-01-01 2021-03-31 0001610950 synh:CommercialSolutionsSegmentMember 2021-01-01 2021-03-31 0001610950 synh:ClinicalSolutionsSegmentMember 2021-03-31 0001610950 synh:CommercialSolutionsSegmentMember 2021-03-31 0001610950 us-gaap:AccumulatedTranslationAdjustmentMember 2020-12-31 0001610950 us-gaap:AccumulatedTranslationAdjustmentMember 2019-12-31 0001610950 us-gaap:AccumulatedTranslationAdjustmentMember 2021-01-01 2021-03-31 0001610950 us-gaap:AccumulatedTranslationAdjustmentMember 2020-01-01 2020-03-31 0001610950 us-gaap:AccumulatedTranslationAdjustmentMember 2021-03-31 0001610950 us-gaap:AccumulatedTranslationAdjustmentMember 2020-03-31 0001610950 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-12-31 0001610950 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-12-31 0001610950 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2021-01-01 2021-03-31 0001610950 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-01-01 2020-03-31 0001610950 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2021-03-31 0001610950 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-03-31 0001610950 2020-12-08 2020-12-09 0001610950 synh:SynteractAcquisitionMember 2020-12-08 2020-12-09 xbrli:pure 0001610950 synh:SynteractAcquisitionMember 2020-12-09 0001610950 synh:SynteractAcquisitionMember 2021-01-01 2021-03-31 0001610950 synh:IllingworthResearchMember 2020-12-16 2020-12-17 0001610950 synh:IllingworthResearchMember 2021-01-01 2021-03-31 0001610950 synh:IllingworthResearchMember 2020-12-17 0001610950 us-gaap:SecuredDebtMember synh:TermLoanATrancheOneDueMarch2024Member 2021-03-31 0001610950 us-gaap:SecuredDebtMember synh:TermLoanATrancheOneDueMarch2024Member 2020-12-31 0001610950 us-gaap:SecuredDebtMember synh:TermLoanATrancheTwoDueAugust2024Member 2021-03-31 0001610950 us-gaap:SecuredDebtMember synh:TermLoanATrancheTwoDueAugust2024Member 2020-12-31 0001610950 us-gaap:SecuredDebtMember synh:A2017CreditAgreementAmendmentNo2TermLoanBDueAugust2024Member 2021-03-31 0001610950 us-gaap:SecuredDebtMember synh:A2017CreditAgreementAmendmentNo2TermLoanBDueAugust2024Member 2020-12-31 0001610950 us-gaap:SecuredDebtMember synh:AccountsReceivableFinancingAgreementDueOctober2022Member synh:AccountsReceivableSecuritizationMember 2021-03-31 0001610950 us-gaap:SecuredDebtMember synh:AccountsReceivableFinancingAgreementDueOctober2022Member synh:AccountsReceivableSecuritizationMember 2020-12-31 0001610950 us-gaap:SecuredDebtMember 2021-03-31 0001610950 us-gaap:SecuredDebtMember 2020-12-31 0001610950 us-gaap:UnsecuredDebtMember synh:SeniorUnsecuredNotesDue2029Member 2021-03-31 0001610950 us-gaap:UnsecuredDebtMember synh:SeniorUnsecuredNotesDue2029Member 2020-12-31 0001610950 us-gaap:UnsecuredDebtMember 2021-03-31 0001610950 us-gaap:UnsecuredDebtMember 2020-12-31 0001610950 synh:A2017CreditAgreementAmendmentNo2TermLoanADueMarch2024Member synh:TermLoanMember us-gaap:SecuredDebtMember 2021-03-31 0001610950 synh:A2017CreditAgreementTermLoanBDueAugust2024Member synh:TermLoanMember us-gaap:SecuredDebtMember 2021-03-31 0001610950 synh:A2017CreditAgreementAmendmentNo2RevolvingCreditFacilityDueAugust2024Member us-gaap:RevolvingCreditFacilityMember us-gaap:SecuredDebtMember 2021-03-31 0001610950 synh:A2017CreditAgreementAmendmentNo2RevolvingCreditFacilityDueAugust2024Member us-gaap:SecuredDebtMember 2021-02-27 2021-02-28 0001610950 synh:A2017CreditAgreementAmendmentNo2RevolvingCreditFacilityDueAugust2024Member synh:TermLoanMember us-gaap:SecuredDebtMember srt:MaximumMember 2021-02-28 0001610950 synh:A2017CreditAgreementAmendmentNo2RevolvingCreditFacilityDueAugust2024Member synh:TermLoanMember us-gaap:SecuredDebtMember srt:MinimumMember 2021-02-28 0001610950 synh:A2017CreditAgreementAmendmentNo2TermLoanADueMarch2024Member us-gaap:SecuredDebtMember 2021-01-01 2021-03-31 0001610950 synh:A2017CreditAgreementTermLoanBDueAugust2024Member us-gaap:SecuredDebtMember 2021-01-01 2021-03-31 0001610950 synh:A2017CreditAgreementRevolvingCreditFacilityDueAugust2024Member us-gaap:LetterOfCreditMember us-gaap:SecuredDebtMember 2021-03-31 0001610950 us-gaap:RevolvingCreditFacilityMember us-gaap:SecuredDebtMember 2021-03-31 0001610950 synh:A2017CreditAgreementRevolvingCreditFacilityDueAugust2024Member us-gaap:SecuredDebtMember 2021-03-31 0001610950 us-gaap:LetterOfCreditMember us-gaap:SecuredDebtMember 2021-03-31 0001610950 synh:AccountsReceivableFinancingAgreementDueOctober2022Member synh:AccountsReceivableSecuritizationMember us-gaap:SecuredDebtMember srt:SubsidiariesMember 2021-01-27 0001610950 synh:AccountsReceivableFinancingAgreementDueOctober2022Member synh:AccountsReceivableSecuritizationMember us-gaap:SecuredDebtMember srt:SubsidiariesMember 2021-01-28 0001610950 synh:AccountsReceivableFinancingAgreementDueOctober2022Member 2021-01-26 2021-01-28 0001610950 synh:AccountsReceivableFinancingAgreementDueOctober2022Member synh:AccountsReceivableSecuritizationMember us-gaap:SecuredDebtMember srt:SubsidiariesMember synh:FederalFundsRateMember 2021-01-01 2021-03-31 0001610950 synh:AccountsReceivableFinancingAgreementDueSeptember2021Member synh:AccountsReceivableSecuritizationMember us-gaap:SecuredDebtMember 2021-03-31 0001610950 srt:SubsidiariesMember synh:AccountsReceivableFinancingAgreementDueSeptember2021Member synh:AccountsReceivableSecuritizationMember us-gaap:SecuredDebtMember 2021-03-31 0001610950 synh:InterestRateSwapExpiringJune302021Member 2018-12-31 0001610950 synh:InterestRateSwapExpiringJune302021Member 2021-03-31 0001610950 synh:InterestRateSwapExpiringMarch312023Member 2020-03-31 0001610950 synh:InterestRateSwapExpiringMarch312023Member srt:ScenarioForecastMember 2021-06-30 0001610950 synh:InterestRateSwapExpiringMarch312023Member 2021-03-31 0001610950 us-gaap:ForeignExchangeForwardMember 2021-03-31 0001610950 us-gaap:ForeignExchangeForwardMember 2021-01-01 2021-03-31 0001610950 us-gaap:AccruedLiabilitiesMember us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CashFlowHedgingMember 2021-03-31 0001610950 us-gaap:AccruedLiabilitiesMember us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CashFlowHedgingMember 2020-12-31 0001610950 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CashFlowHedgingMember 2021-03-31 0001610950 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CashFlowHedgingMember 2020-12-31 0001610950 us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CashFlowHedgingMember 2021-03-31 0001610950 us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CashFlowHedgingMember 2020-12-31 0001610950 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0001610950 us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0001610950 us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember srt:PartnershipInterestMember us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0001610950 srt:PartnershipInterestMember us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0001610950 us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0001610950 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0001610950 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001610950 us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001610950 us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember srt:PartnershipInterestMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001610950 srt:PartnershipInterestMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001610950 us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001610950 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001610950 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001610950 synh:HealthcareAndLifeSciencesIndustryMember 2021-03-31 synh:EquityFund 0001610950 us-gaap:FairValueMeasurementsNonrecurringMember 2021-03-31 0001610950 us-gaap:FairValueMeasurementsNonrecurringMember 2020-12-31 0001610950 us-gaap:FairValueInputsLevel2Member us-gaap:SecuredDebtMember us-gaap:CarryingReportedAmountFairValueDisclosureMember synh:A2017CreditAgreementAmendmentNo2TermLoanATrancheOneDueMarch2024Member 2021-03-31 0001610950 us-gaap:FairValueInputsLevel2Member us-gaap:SecuredDebtMember us-gaap:CarryingReportedAmountFairValueDisclosureMember synh:A2017CreditAgreementAmendmentNo2TermLoanATrancheTwoDueAugust2024Member 2021-03-31 0001610950 us-gaap:FairValueInputsLevel2Member us-gaap:SecuredDebtMember us-gaap:CarryingReportedAmountFairValueDisclosureMember synh:A2017CreditAgreementAmendmentNo2TermLoanBDueAugust2024Member 2021-03-31 0001610950 us-gaap:FairValueInputsLevel2Member us-gaap:SecuredDebtMember us-gaap:EstimateOfFairValueFairValueDisclosureMember synh:A2017CreditAgreementAmendmentNo2TermLoanATrancheOneDueMarch2024Member 2021-03-31 0001610950 us-gaap:FairValueInputsLevel2Member us-gaap:SecuredDebtMember us-gaap:EstimateOfFairValueFairValueDisclosureMember synh:A2017CreditAgreementAmendmentNo2TermLoanATrancheTwoDueAugust2024Member 2021-03-31 0001610950 us-gaap:FairValueInputsLevel2Member us-gaap:SecuredDebtMember us-gaap:EstimateOfFairValueFairValueDisclosureMember synh:A2017CreditAgreementAmendmentNo2TermLoanBDueAugust2024Member 2021-03-31 0001610950 us-gaap:FairValueInputsLevel2Member us-gaap:SecuredDebtMember us-gaap:CarryingReportedAmountFairValueDisclosureMember synh:A2017CreditAgreementAmendmentNo2TermLoanATrancheOneDueMarch2024Member 2020-12-31 0001610950 us-gaap:FairValueInputsLevel2Member us-gaap:SecuredDebtMember us-gaap:CarryingReportedAmountFairValueDisclosureMember synh:A2017CreditAgreementAmendmentNo2TermLoanATrancheTwoDueAugust2024Member 2020-12-31 0001610950 us-gaap:FairValueInputsLevel2Member us-gaap:SecuredDebtMember us-gaap:CarryingReportedAmountFairValueDisclosureMember synh:A2017CreditAgreementAmendmentNo2TermLoanBDueAugust2024Member 2020-12-31 0001610950 us-gaap:FairValueInputsLevel2Member us-gaap:SecuredDebtMember us-gaap:EstimateOfFairValueFairValueDisclosureMember synh:A2017CreditAgreementAmendmentNo2TermLoanATrancheOneDueMarch2024Member 2020-12-31 0001610950 us-gaap:FairValueInputsLevel2Member us-gaap:SecuredDebtMember us-gaap:EstimateOfFairValueFairValueDisclosureMember synh:A2017CreditAgreementAmendmentNo2TermLoanATrancheTwoDueAugust2024Member 2020-12-31 0001610950 us-gaap:FairValueInputsLevel2Member us-gaap:SecuredDebtMember us-gaap:EstimateOfFairValueFairValueDisclosureMember synh:A2017CreditAgreementAmendmentNo2TermLoanBDueAugust2024Member 2020-12-31 0001610950 us-gaap:FairValueInputsLevel2Member us-gaap:UnsecuredDebtMember us-gaap:CarryingReportedAmountFairValueDisclosureMember synh:SeniorUnsecuredNoteDue2029Member 2021-03-31 0001610950 us-gaap:FairValueInputsLevel2Member us-gaap:UnsecuredDebtMember us-gaap:EstimateOfFairValueFairValueDisclosureMember synh:SeniorUnsecuredNoteDue2029Member 2021-03-31 0001610950 us-gaap:FairValueInputsLevel2Member us-gaap:UnsecuredDebtMember us-gaap:CarryingReportedAmountFairValueDisclosureMember synh:SeniorUnsecuredNoteDue2029Member 2020-12-31 0001610950 us-gaap:FairValueInputsLevel2Member us-gaap:UnsecuredDebtMember us-gaap:EstimateOfFairValueFairValueDisclosureMember synh:SeniorUnsecuredNoteDue2029Member 2020-12-31 0001610950 us-gaap:EmployeeSeveranceMember 2021-01-01 2021-03-31 0001610950 us-gaap:EmployeeSeveranceMember 2020-01-01 2020-03-31 0001610950 us-gaap:FacilityClosingMember 2021-01-01 2021-03-31 0001610950 us-gaap:FacilityClosingMember 2020-01-01 2020-03-31 0001610950 us-gaap:OtherRestructuringMember 2021-01-01 2021-03-31 0001610950 us-gaap:OtherRestructuringMember 2020-01-01 2020-03-31 0001610950 us-gaap:EmployeeSeveranceMember us-gaap:BusinessRestructuringReservesMember 2020-12-31 0001610950 us-gaap:BusinessRestructuringReservesMember 2020-12-31 0001610950 us-gaap:EmployeeSeveranceMember us-gaap:BusinessRestructuringReservesMember 2021-01-01 2021-03-31 0001610950 us-gaap:OtherRestructuringMember us-gaap:BusinessRestructuringReservesMember 2021-01-01 2021-03-31 0001610950 us-gaap:BusinessRestructuringReservesMember 2021-01-01 2021-03-31 0001610950 us-gaap:EmployeeSeveranceMember us-gaap:BusinessRestructuringReservesMember 2021-03-31 0001610950 us-gaap:BusinessRestructuringReservesMember 2021-03-31 0001610950 us-gaap:CommonClassAMember 2020-11-17 0001610950 us-gaap:CommonClassAMember 2021-01-01 2021-03-31 0001610950 us-gaap:CommonStockMember 2021-02-01 2021-02-28 0001610950 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001610950 us-gaap:CommonStockMember 2021-03-31 0001610950 us-gaap:ForeignCountryMember 2021-01-01 2021-03-31 0001610950 srt:MinimumMember 2021-01-01 2021-03-31 0001610950 srt:MaximumMember 2021-01-01 2021-03-31 0001610950 synh:ClinicalSolutionsSegmentMember us-gaap:OperatingSegmentsMember 2021-01-01 2021-03-31 0001610950 synh:ClinicalSolutionsSegmentMember us-gaap:OperatingSegmentsMember 2020-01-01 2020-03-31 0001610950 synh:CommercialSolutionsSegmentMember us-gaap:OperatingSegmentsMember 2021-01-01 2021-03-31 0001610950 synh:CommercialSolutionsSegmentMember us-gaap:OperatingSegmentsMember 2020-01-01 2020-03-31 0001610950 us-gaap:OperatingSegmentsMember 2021-01-01 2021-03-31 0001610950 us-gaap:OperatingSegmentsMember 2020-01-01 2020-03-31 0001610950 us-gaap:CorporateNonSegmentMember synh:CostofServicesMember 2021-01-01 2021-03-31 0001610950 us-gaap:CorporateNonSegmentMember synh:CostofServicesMember 2020-01-01 2020-03-31 0001610950 us-gaap:CorporateNonSegmentMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2021-01-01 2021-03-31 0001610950 us-gaap:CorporateNonSegmentMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2020-01-01 2020-03-31 0001610950 us-gaap:CorporateNonSegmentMember 2021-01-01 2021-03-31 0001610950 us-gaap:CorporateNonSegmentMember 2020-01-01 2020-03-31 0001610950 srt:NorthAmericaMember 2021-01-01 2021-03-31 0001610950 srt:NorthAmericaMember 2020-01-01 2020-03-31 0001610950 us-gaap:EMEAMember 2021-01-01 2021-03-31 0001610950 us-gaap:EMEAMember 2020-01-01 2020-03-31 0001610950 srt:AsiaPacificMember 2021-01-01 2021-03-31 0001610950 srt:AsiaPacificMember 2020-01-01 2020-03-31 0001610950 srt:LatinAmericaMember 2021-01-01 2021-03-31 0001610950 srt:LatinAmericaMember 2020-01-01 2020-03-31 0001610950 country:US 2021-01-01 2021-03-31 0001610950 country:US 2020-01-01 2020-03-31 0001610950 country:US us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2021-01-01 2021-03-31 0001610950 country:US us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2020-01-01 2020-03-31 0001610950 srt:NorthAmericaMember 2021-03-31 0001610950 srt:NorthAmericaMember 2020-12-31 0001610950 us-gaap:EMEAMember 2021-03-31 0001610950 us-gaap:EMEAMember 2020-12-31 0001610950 srt:AsiaPacificMember 2021-03-31 0001610950 srt:AsiaPacificMember 2020-12-31 0001610950 srt:LatinAmericaMember 2021-03-31 0001610950 srt:LatinAmericaMember 2020-12-31 0001610950 country:US 2021-03-31 0001610950 country:US 2020-12-31 0001610950 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember 2021-01-01 2021-03-31 0001610950 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember 2020-01-01 2020-03-31 0001610950 us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember 2021-01-01 2021-03-31 0001610950 us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember 2020-01-01 2020-12-31 0001610950 srt:DirectorMember 2021-01-01 2021-03-31 synh:Customer synh:numberOfAction 0001610950 us-gaap:PendingLitigationMember synh:BermudezAndVaitkuvieneActionsMember 2017-12-01 2017-12-01 0001610950 us-gaap:PendingLitigationMember synh:BermudezAndVaitkuvieneActionsMember 2018-01-30 2018-01-30 0001610950 synh:InVentivMergerMember us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0001610950 synh:InVentivMergerMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM i 10-Q

(Mark One)


i ☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended i March 31, 2021


i ☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to .

Commission File Number: i 001-36730

i SYNEOS HEALTH, INC.

(Exact name of registrant as specified in its charter)


i Delaware		i 27-3403111
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

i 1030 Sync Street, i Morrisville, i North Carolina i 27560-5468

(Address of principal executive offices and Zip Code)

( i 919) i 876-9300

(Registrant’s telephone number, including area code)

N/A

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
i Class A Common Stock, $0.01 par value per share	i SYNH	i The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. i Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically, every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). i Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.


i Large accelerated filer	☒	Accelerated filer	☐
Non-accelerated filer	☐	Smaller reporting company	i ☐
		Emerging growth company	i ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes i ☐ No ☒

As of April 26, 2021, there were approximately i 104,292,460 shares of the registrant’s common stock outstanding.

Table of Contents

SYNEOS HEALTH, INC.

FORM 10-Q

TABLE OF CONTENTS

	PART I - FINANCIAL INFORMATION

		Page

Item 1.	Financial Statements	3

	Condensed Consolidated Statements of Income for the three months ended March 31, 2021 and 2020 (unaudited)	3

	Condensed Consolidated Statements of Comprehensive Income (Loss) for the three months ended March 31, 2021 and 2020 (unaudited)	4

	Condensed Consolidated Balance Sheets as of March 31, 2021 and December 31, 2020 (unaudited)	5

	Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2021 and 2020 (unaudited)	6

	Condensed Consolidated Statements of Shareholders’ Equity for the three months ended March 31, 2021 and 2020 (unaudited)	7

	Notes to Condensed Consolidated Financial Statements (unaudited)	8

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	25

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	38

Item 4.	Controls and Procedures	38

	PART II - OTHER INFORMATION

Item 1.	Legal Proceedings	38

Item 1A.	Risk Factors	38

Item 2.	Unregistered Sales of Equity Securities, Use of Proceeds and Issuer Purchases of Equity Securities	38

Item 5.	Other Information	39

Item 6.	Exhibits	40

	Signature	41

Table of Contents

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements.

SYNEOS HEALTH, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(Unaudited)

	Three Months Ended March 31,
	2021			2020
	(in thousands, except per share data)
Revenue	$	i 1,208,745		$	i 1,163,355

Costs and operating expenses:
Direct costs (exclusive of depreciation and amortization)		i 945,250			i 924,014
Selling, general, and administrative expenses		i 137,314			i 125,547
Restructuring and other costs		i 7,228			i 8,720
Depreciation		i 18,447			i 17,225
Amortization		i 39,491			i 38,882
Total operating expenses		i 1,147,730			i 1,114,388
Income from operations		i 61,015			i 48,967

Total other expense, net:
Interest income		( i 71	)		( i 336	)
Interest expense		i 23,328			i 26,458
Loss on extinguishment of debt		i 603			—
Other income, net		( i 9,856	)		( i 18,930	)
Total other expense, net		i 14,004			i 7,192
Income before provision for income taxes		i 47,011			i 41,775
Income tax expense		i 8,287			i 8,201
Net income	$	i 38,724		$	i 33,574

Earnings per share:
Basic	$	i 0.37		$	i 0.32
Diluted	$	i 0.37		$	i 0.32
Weighted average common shares outstanding:
Basic		i 104,274			i 104,265
Diluted		i 105,457			i 105,642

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

SYNEOS HEALTH, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)

(Unaudited)

	Three Months Ended March 31,
	2021			2020
	(in thousands)
Net income	$	i 38,724		$	i 33,574
Unrealized gain (loss) on derivative instruments, net of income tax expense (benefit) of $ i 2,013 and $( i 6,639), respectively		i 5,937			( i 10,730	)
Foreign currency translation adjustments, net of income tax benefit of $ i 708 and $ i 0, respectively		( i 4,310	)		( i 48,788	)
Comprehensive income (loss)	$	i 40,351		$	( i 25,944	)

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

SYNEOS HEALTH, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

	March 31, 2021			December 31, 2020
	(in thousands, except par value)
ASSETS
Current assets:
Cash, cash equivalents, and restricted cash	$	i 264,689		$	i 272,173
Accounts receivable and unbilled services, net		i 1,299,168			i 1,344,781
Prepaid expenses and other current assets		i 110,521			i 121,058
Total current assets		i 1,674,378			i 1,738,012
Property and equipment, net		i 202,618			i 216,200
Operating lease right-of-use assets		i 215,048			i 223,285
Goodwill		i 4,780,179			i 4,776,178
Intangible assets, net		i 896,386			i 933,525
Deferred income tax assets		i 34,964			i 35,059
Other long-term assets		i 151,076			i 141,047
Total assets	$	i 7,954,649		$	i 8,063,306

LIABILITIES AND SHAREHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$	i 113,881		$	i 113,684
Accrued expenses		i 587,757			i 611,042
Deferred revenue		i 773,025			i 793,068
Current portion of operating lease obligations		i 40,759			i 42,082
Current portion of finance lease obligations		i 16,863			i 17,455
Total current liabilities		i 1,532,285			i 1,577,331
Long-term debt		i 2,862,574			i 2,902,054
Operating lease long-term obligations		i 213,662			i 221,760
Finance lease long-term obligations		i 27,768			i 31,522
Deferred income tax liabilities		i 17,043			i 20,216
Other long-term liabilities		i 64,440			i 68,311
Total liabilities		i 4,717,772			i 4,821,194

Commitments and contingencies (Note 16)

Shareholders’ equity:
Preferred stock, $ i i 0.01 / par value; i i 30,000 / shares authorized, i i i i 0 / / / shares issued and outstanding at March 31, 2021 and December 31, 2020		i —			i —
Common stock, $ i i 0.01 / par value; i i 600,000 / shares authorized, i i 104,226 / and i i 103,935 / shares issued and outstanding at March 31, 2021 and December 31, 2020, respectively		i 1,042			i 1,039
Additional paid-in capital		i 3,440,840			i 3,461,747
Accumulated other comprehensive loss, net of taxes		( i 39,174	)		( i 40,801	)
Accumulated deficit		( i 165,831	)		( i 179,873	)
Total shareholders’ equity		i 3,236,877			i 3,242,112
Total liabilities and shareholders’ equity	$	i 7,954,649		$	i 8,063,306

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

SYNEOS HEALTH, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

	Three Months Ended March 31,
	2021			2020
	(in thousands)
Cash flows from operating activities:
Net income	$	i 38,724		$	i 33,574
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Depreciation and amortization		i 57,938			i 56,107
Share-based compensation		i 17,353			i 15,998
(Recovery from) provision for doubtful accounts		( i 187	)		i 271
(Benefit from) provision for deferred income taxes		( i 4,653	)		i 8,159
Foreign currency transaction gains		( i 9,522	)		( i 15,019	)
Fair value adjustment of contingent obligations		( i 597	)		( i 4,095	)
Loss on extinguishment of debt		i 603			i —
Other non-cash items		i 953			i 1,104
Changes in operating assets and liabilities, net of effect of business combinations:
Accounts receivable, unbilled services, and deferred revenue		i 30,997			( i 53,078	)
Accounts payable and accrued expenses		i 518			( i 66,426	)
Other assets and liabilities		( i 5,039	)		( i 15,202	)
Net cash provided by (used in) operating activities		i 127,088			( i 38,607	)
Cash flows from investing activities:
Payments related to acquisition of business, net of cash acquired		( i 9,982	)		i —
Purchases of property and equipment		( i 11,173	)		( i 11,870	)
Proceeds from (investments in) unconsolidated affiliates		i 1,374			( i 6,750	)
Net cash used in investing activities		( i 19,781	)		( i 18,620	)
Cash flows from financing activities:
Payments of debt financing costs		( i 49	)		i —
Repayments of long-term debt		( i 105,856	)		i —
Proceeds from accounts receivable financing agreement		i 65,000			i 6,600
Repayments of accounts receivable financing agreement		i —			( i 6,600	)
Proceeds from revolving line of credit		i —			i 300,000
Payments of contingent consideration related to business combinations		( i 6,196	)		( i 26,592	)
Payments of finance leases		( i 4,269	)		( i 4,674	)
Payments for repurchases of common stock		( i 44,505	)		( i 32,029	)
Proceeds from exercises of stock options		i 10,804			i 12,358
Payments related to tax withholdings for share-based compensation		( i 26,295	)		( i 19,145	)
Net cash (used in) provided by financing activities		( i 111,366	)		i 229,918
Effect of exchange rate changes on cash, cash equivalents, and restricted cash		( i 3,425	)		( i 420	)
Net change in cash, cash equivalents, and restricted cash		( i 7,484	)		i 172,271
Cash, cash equivalents, and restricted cash - beginning of period		i 272,173			i 163,689
Cash, cash equivalents, and restricted cash - end of period	$	i 264,689		$	i 335,960

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

SYNEOS HEALTH, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY

(Unaudited)

	Three Months Ended March 31,
	2021			2020
	(in thousands)
Shareholders’ equity, beginning balance	$	i 3,242,112		$	i 3,029,654
Impact from adoption of ASU 2016-13		—			( i 2,771	)
Shareholders’ equity, adjusted beginning balance		i 3,242,112			i 3,026,883

Common stock:
Beginning balance		i 1,039			i 1,039
Repurchases of common stock		( i 6	)		( i 6	)
Issuances of common stock		i 9			i 9
Ending balance		i 1,042			i 1,042

Additional paid-in capital:
Beginning balance		i 3,461,747			i 3,441,471
Repurchases of common stock		( i 19,817	)		( i 19,734	)
Issuances of common stock		( i 18,443	)		( i 6,995	)
Share-based compensation		i 17,353			i 15,998
Ending balance		i 3,440,840			i 3,430,740

Accumulated other comprehensive loss:
Beginning balance		( i 40,801	)		( i 71,593	)
Unrealized gain (loss) on derivative instruments, net of taxes		i 5,937			( i 10,730	)
Foreign currency translation adjustment, net of taxes		( i 4,310	)		( i 48,788	)
Ending balance		( i 39,174	)		( i 131,111	)

Accumulated deficit:
Beginning balance		( i 179,873	)		( i 341,263	)
Impact from adoption of ASU 2016-13		—			( i 2,771	)
Adjusted beginning balance		( i 179,873	)		( i 344,034	)
Repurchases of common stock		( i 24,682	)		( i 12,289	)
Net income		i 38,724			i 33,574
Ending balance		( i 165,831	)		( i 322,749	)

Shareholders’ equity, ending balance	$	i 3,236,877		$	i 2,977,922

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

SYNEOS HEALTH, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

1. Basis of Presentation and Changes in Significant Accounting Policies

Nature of Operations

Syneos Health, Inc. (the “Company”) is a global provider of end-to-end biopharmaceutical outsourcing solutions. The Company operates under i two reportable segments, Clinical Solutions and Commercial Solutions, and derives its revenue through a suite of services designed to enhance its customers’ ability to successfully develop, launch, and market their products. The Company offers its solutions on both a standalone and integrated basis with biopharmaceutical development and commercialization services ranging from Phase I to IV clinical trial services to services associated with the commercialization of biopharmaceutical products. The Company’s customers include small, mid-sized, and large companies in the pharmaceutical, biotechnology, and medical device industries.

Unaudited Interim Financial Information

The Company prepared the accompanying unaudited condensed consolidated financial statements in accordance with generally accepted accounting principles in the United States of America (“GAAP”) for interim financial information. The significant accounting policies followed by the Company for interim financial reporting are consistent with the accounting policies followed for annual financial reporting.

The unaudited condensed consolidated financial statements, in management’s opinion, include all adjustments of a normal recurring nature necessary for a fair presentation. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the Company’s audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020, filed with the Securities and Exchange Commission on February 18, 2021. The results of operations for the three months ended March 31, 2021 are not necessarily indicative of the results to be expected for the full year ending December 31, 2021 or any other future period. The unaudited condensed consolidated balance sheet at December 31, 2020 is derived from the amounts in the audited consolidated balance sheet included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020.

Reclassification

Certain previously reported amounts have been reclassified to conform to the current year presentation.

COVID-19 Pandemic

On March 11, 2020, the World Health Organization designated the outbreak of the novel strain of coronavirus that causes the disease known as COVID-19 as a global pandemic. Governments and businesses around the world have taken unprecedented actions to mitigate the spread of COVID-19, including, but not limited to, shelter-in-place orders, quarantines, significant restrictions on travel, social distancing practices as well as restrictions that prohibit many employees from going to work in person. As a result, the Company experienced significant impacts to its business and results of operations from COVID-19 during 2020 and for the three months ended March 31, 2021. While certain governments have eased restrictions, the pandemic continues to be disruptive to the Company’s business. The pandemic and associated economic impacts are expected to continue to significantly impact the Company’s future financial condition, results of operations, and cash flows.

Table of Contents

2. Financial Statement Details

Cash, Cash Equivalents, and Restricted Cash

Certain of the Company’s subsidiaries participate in a notional cash pooling arrangement to manage global liquidity requirements. As part of a master netting arrangement, the participants combine their cash balances in pooling accounts at the same financial institution with the ability to offset bank overdrafts of one participant against positive cash account balances held by another participant. Under the terms of the master netting arrangement, the financial institution has the right, ability, and intent to offset a positive balance in one account against an overdrawn amount in another account. Amounts in each of the accounts are unencumbered and unrestricted with respect to use. As such, the net cash balance related to this pooling arrangement is included in cash, cash equivalents, and restricted cash in the unaudited condensed consolidated balance sheets.

The Company’s net cash pool position consisted of the following (in thousands):

	March 31, 2021			December 31, 2020
Gross cash position	$	i 193,053		$	i 220,261
Less: cash borrowings		( i 178,715	)		( i 204,647	)
Net cash position	$	i 14,338		$	i 15,614

Accounts Receivable and Unbilled Services, net

Accounts receivable and unbilled services (including contract assets), net of allowance for doubtful accounts, consisted of the following (in thousands):

	March 31, 2021			December 31, 2020
Accounts receivable billed	$	i 705,783		$	i 774,605
Accounts receivable unbilled		i 228,798			i 211,285
Contract assets		i 372,266			i 366,506
Less: Allowance for doubtful accounts		( i 7,679	)		( i 7,615	)
Accounts receivable and unbilled services, net	$	i 1,299,168		$	i 1,344,781

Accounts Receivable Factoring Arrangement

The Company has an accounts receivable factoring agreement to sell certain eligible unsecured trade accounts receivable, without recourse, to an unrelated third-party financial institution for cash. For the three months ended March 31, 2021 and 2020, the Company factored $ i 30.1 million and $ i 36.2 million, respectively, of trade accounts receivable on a non-recourse basis and received $ i 30.0 million and $ i 36.0 million, respectively, in cash proceeds from the sale. The fees associated with these transactions were insignificant.

Goodwill

The changes in the carrying amount of goodwill by segment for the three months ended March 31, 2021 were as follows (in thousands):

Clinical

Solutions (a)

Commercial

Solutions (b)

Total

Balance as of December 31, 2020

i 3,216,335

i 1,559,843

i 4,776,178

Business combinations (c)

i 2,479

—

i 2,479

Impact of foreign currency translation and other (d)

i 49,079

( i 47,557

)

i 1,522

Balance as of March 31, 2021

i 3,267,893

i 1,512,286

i 4,780,179

/ /

Table of Contents

(a) Accumulated impairment losses of $ i i 8.1 / million associated with the Clinical Solutions segment were recorded prior to 2016 and related to the former Phase I Services segment, now a component of the Clinical Solutions segment. i No impairment of goodwill was recorded for the three months ended March 31, 2021.

(b) Accumulated impairment losses of $ i i 8.0 / million associated with the Commercial Solutions segment were recorded prior to 2015 and related to the former Global Consulting segment, now a component of the Commercial Solutions segment. i No impairment of goodwill was recorded for the three months ended March 31, 2021.

(c) Amount represents measurement period adjustments to goodwill recognized in connection with the 2020 acquisitions of SHCR Holdings Corporation (“Synteract”) and Illingworth Research Group™ (“Illingworth Research”) within the Clinical Solutions segment.

(d) Includes $ i 44.2 million reallocation of goodwill from the Commercial Solutions segment to the Clinical Solutions segment to reflect the transfer of the Kinapse Regulatory and Operations Consulting service lines to align with management reporting in 2021.

Accumulated Other Comprehensive Loss, Net of Taxes

Accumulated other comprehensive loss, net of taxes, consisted of the following (in thousands):

	Three Months Ended March 31,
	2021			2020
Beginning balance	$	( i 40,801	)	$	( i 71,593	)

Foreign currency translation:
Beginning balance		( i 22,040	)		( i 56,757	)
Other comprehensive loss before reclassifications		( i 4,310	)		( i 48,788	)
Ending balance		( i 26,350	)		( i 105,545	)

Derivative instruments:
Beginning balance		( i 18,761	)		( i 14,836	)
Other comprehensive income (loss) before reclassifications		i i 772 /			( i i 12,510 /	)
Reclassification adjustments		i 5,165			i 1,780
Ending balance		( i 12,824	)		( i 25,566	)

Accumulated other comprehensive loss, net of taxes	$	( i 39,174	)	$	( i 131,111	)

/ i

Changes in accumulated other comprehensive loss consisted of the following (in thousands):

	Three Months Ended March 31,
	2021			2020
Foreign currency translation adjustments:
Foreign currency translation adjustment, before taxes	$	( i 5,018	)	$	( i 48,788	)
Income tax benefit		( i 708	)		—
Foreign currency translation adjustments, net of taxes		( i 4,310	)		( i 48,788	)
Unrealized loss on derivative instruments:
Unrealized gain (loss) during period, before taxes		i 1,034			( i 19,783	)
Income tax expense (benefit)		i 262			( i 7,273	)
Unrealized gain (loss) during period, net of taxes		i 772			( i 12,510	)
Reclassification adjustment, before taxes		i 6,916			i 2,414
Income tax expense		i 1,751			i 634
Reclassification adjustment, net of taxes		i 5,165			i 1,780
Total unrealized gain (loss) on derivative instruments, net of taxes		i 5,937			( i 10,730	)
Total other comprehensive income (loss), net of taxes	$	i 1,627		$	( i 59,518	)

Table of Contents

Other Income, Net

Other income, net consisted of the following (in thousands):

	Three Months Ended March 31,
	2021			2020
Net realized foreign currency loss (gain)	$	i 1,192		$	( i 5,096	)
Net unrealized foreign currency gain		( i 9,522	)		( i 15,019	)
Other, net		( i 1,526	)		i 1,185
Total other income, net	$	( i 9,856	)	$	( i 18,930	)

3. Business Combinations

Synteract Acquisition

On i December 9, 2020, the Company completed the acquisition of i Synteract, effected through the purchase of i 100% of the outstanding shares of Synteract for approximately $ i 385.5 million in cash (net of approximately $ i 28.0 million of cash acquired), which includes payment of $ i 1.0 million during the three months ended March 31, 2021. Synteract is a contract research organization focused on the emerging biopharmaceutical industry, strengthening the Company’s position in the small to mid-sized category. The Company recognized $ i 357.1 million of goodwill and $ i 56.4 million of intangible assets, including acquired backlog and trade name, as a result of the acquisition. The purchase price has been allocated to the tangible assets and identifiable intangible assets acquired and liabilities assumed based upon their fair values. The excess of the purchase price over the tangible and intangible assets acquired and liabilities assumed has been recorded as goodwill. Goodwill is attributable to the acquired workforce as well as future synergies and is not deductible for income tax purposes. The operating results from the acquisition of Synteract have been included in the Company’s Clinical Solutions segment from the date of acquisition.

Illingworth Research Group Acquisition

On i December 17, 2020, the Company completed the acquisition of Illingworth Research, a leading provider of clinical research home health services, adding new scale and capabilities to the Company’s clinical trial solutions. The total purchase consideration was $ i 80.9 million (net of cash acquired of $ i 1.1 million), which includes payments of $ i 9.0 million during the three months ended March 31, 2021. The Company recognized $ i 64.0 million of goodwill and $ i 21.5 million of intangible assets, principally customer relationships, as a result of the acquisition. The purchase price has been allocated to the tangible assets and identifiable intangible assets acquired and liabilities assumed based upon their fair values. The excess of the purchase price over the tangible and intangible assets acquired and liabilities assumed has been recorded as goodwill. Goodwill is attributable to the acquired workforce as well as future synergies and is not deductible for income tax purposes. The operating results from the acquisition of Illingworth Research have been included in the Company’s Clinical Solutions segment from the date of acquisition.

The Company’s assessment of fair value and the purchase price allocation related to these 2020 acquisitions is preliminary and further adjustments may be necessary as additional information related to the fair values of assets acquired and liabilities assumed is assessed during the measurement period (up to one year from the respective acquisition dates).

Pro forma information for these acquisitions is not presented as the operations of the acquired businesses, individually and in the aggregate, are not significant to the overall operations of the Company.

Table of Contents

4. Long-Term Debt Obligations

The Company’s debt obligations consisted of the following (in thousands):

	March 31, 2021			December 31, 2020
Secured Debt
Term Loan A - tranche one due March 2024	$	i 173,852		$	i 183,715
Term Loan A - tranche two due August 2024		i 1,242,140			i 1,273,991
Term Loan B due August 2024		i 496,421			i 560,564
Accounts receivable financing agreement due October 2022		i 365,000			i 300,000
Total secured debt		i 2,277,413			i 2,318,270
Unsecured Debt
3.625% Senior Unsecured Notes due 2029 (the “Notes”)		i 600,000			i 600,000
Total debt obligations		i 2,877,413			i 2,918,270
Less: Term loan original issuance discount		( i 3,108	)		( i 3,500	)
Less: Unamortized deferred issuance costs		( i 11,731	)		( i 12,716	)
Total debt obligations, non-current portion	$	i 2,862,574		$	i 2,902,054

Credit Agreement

The Company is party to a credit agreement (as amended, the “Credit Agreement”) that includes a $ i 1.55 billion Term Loan A facility (“Term Loan A”) that has two tranches, tranche one that matures on March 26, 2024 and tranche two that matures on August 1, 2024, a $ i 1.60 billion Term Loan B facility that matures on August 1, 2024 (“Term Loan B”), and a $ i 600.0 million revolving credit facility that matures on August 1, 2024 (the “Revolver”).

In February 2021, as a result of the Company’s First Lien Leverage Ratio (as defined in the Credit Agreement) being less than or equal to i 2.5x, the Adjusted Eurocurrency Rate Spread (as defined in the Credit Agreement) on Term Loan A and the Revolver decreased from i 1.50% to i 1.25%.

During the three months ended March 31, 2021, the Company made $ i 41.8 million and $ i 64.1 million of voluntary prepayments against Term Loan A and Term Loan B, respectively, which were applied to future principal payments. As a result of these and previous voluntary prepayments, the Company is not required to make a mandatory payment against the principal balance of Term Loan A until October 2022 and Term Loan B until maturity in August 2024.

Revolver and Letters of Credit

The Revolver includes letters of credit (“LOCs”) with a sublimit of $ i 150.0 million. As of March 31, 2021, there were i no outstanding Revolver borrowings and $ i 16.1 million of LOCs outstanding, leaving $ i 583.9 million of available borrowings under the Revolver, including $ i 133.9 million available for LOCs.

The lease for the Company’s corporate headquarters in Morrisville, North Carolina includes a provision that may require the Company to issue a LOC in certain amounts to the landlord based on the debt rating of the Company issued by Moody’s Investors Service (or other nationally-recognized debt rating agency, such as S&P Global Ratings). As of March 31, 2021 (and through the date of this filing), the Company’s debt rating was such that no LOC is currently required. Any LOC issued in accordance with the aforementioned requirements could be issued under the Company’s Revolver, and, if issued under the Revolver, would reduce its available borrowing capacity by the same amount accordingly.

Table of Contents

Accounts Receivable Financing Agreement

The Company has an accounts receivable financing agreement (as amended) with a termination date of October 3, 2022, unless terminated earlier pursuant to its terms. On January 28, 2021, the Company amended this agreement to increase the amount it can borrow from $ i 300.0 million to $ i 365.0 million, and drew down the additional $ i 65.0 million to partially fund the Term Loan A and Term Loan B voluntary prepayments. Accordingly, there was no incremental impact on the Company’s total debt.

Under the accounts receivable financing agreement, certain of the Company’s consolidated subsidiaries sell accounts receivable and unbilled services (including contract assets) balances to a wholly-owned, bankruptcy-remote special purpose entity. The Company has guaranteed the performance of the obligations of existing and future subsidiaries that sell and service the accounts receivable under this agreement. The available borrowing capacity varies monthly according to the levels of the Company’s eligible accounts receivable and unbilled services (including contract assets). Loans under this agreement will accrue interest at a reserve-adjusted LIBOR rate or a base rate equal to the higher of the applicable lender’s prime rate and the federal funds rate plus i 0.50%.

As of March 31, 2021, the Company had $ i 365.0 million of outstanding borrowings under the accounts receivable financing agreement, which are recorded in long-term debt on the accompanying unaudited condensed consolidated balance sheet. There was i no remaining borrowing capacity available under this agreement as of March 31, 2021.

Maturities of Debt Obligations

As of March 31, 2021, the contractual maturities of the Company’s debt obligations (excluding finance leases) were as follows (in thousands):

	Principal
Remainder of 2021	$	—
2022		i 385,856
2023		i 107,313
2024		i 1,784,244
2025		—
2026 and thereafter		i 600,000
Less: Deferred issuance costs		( i 11,731	)
Less: Term loan original issuance discount		( i 3,108	)
Total	$	i 2,862,574

5. Derivatives

Interest Rate Swaps

The Company has entered into various interest rate swaps to mitigate its exposure to changes in interest rates on its term loans.

In June 2018, the Company entered into an interest rate swap with multiple counterparties that had an initial aggregate notional value of $ i 1.01 billion, an effective date of December 31, 2018, and will expire on June 30, 2021. As of March 31, 2021, the notional value of this interest rate swap was $ i 894.0 million.

In March 2020, the Company entered into interest rate swaps with multiple counterparties. The interest rate swaps had an initial aggregate notional value of $ i 549.2 million that will increase to $ i 1.42 billion on June 30, 2021, an effective date of March 31, 2020, and will expire on March 31, 2023. As of March 31, 2021, the notional value of these interest rate swaps was $ i 572.7 million.

Table of Contents

Foreign Exchange Forward

On October 30, 2020, the Company entered into a foreign exchange forward in order to minimize monthly foreign currency remeasurement gains or losses on non-functional currency monetary balances. The foreign exchange forward notional value may be adjusted each month as the exposure balance changes. The Company did not designate the derivative as a hedge. All changes in the fair value of the foreign exchange forward are recorded in earnings every month to other (income) expense, net in the accompanying consolidated statements of income. The Company recognized $ i 1.1 million of realized gains during the three months ended March 31, 2021 related to this foreign exchange forward. As of March 31, 2021, the notional value of this foreign exchange forward was $ i 50.0 million.

Fair Values

The fair values of the Company’s derivative financial instruments and the line items on the accompanying condensed consolidated balance sheets to which they were recorded were as follows (in thousands):

	Balance Sheet Classification	March 31, 2021		December 31, 2020
Interest rate swaps - current	Accrued expenses	$	i 11,507	$	i 17,045
Interest rate swaps - non-current	Other long-term liabilities		i 3,161		i 5,572
Fair value of derivative liabilities		$	i 14,668	$	i 22,617

6. Fair Value Measurements

Assets and Liabilities Carried at Fair Value

As of March 31, 2021 and December 31, 2020, the Company’s financial assets and liabilities carried at fair value included cash and cash equivalents, restricted cash, trading securities, accounts receivable, unbilled services (including contract assets), accounts payable, accrued expenses, deferred revenue, contingent obligations, liabilities under the accounts receivable financing agreement, and derivative instruments.

The fair values of cash and cash equivalents, restricted cash, accounts receivable, unbilled services (including contract assets), accounts payable, accrued expenses, deferred revenue, and the liabilities under the accounts receivable financing agreement approximate their respective carrying amounts because of the liquidity and short-term nature of these financial instruments.

Financial Instruments Subject to Recurring Fair Value Measurements

As of March 31, 2021, the fair values of the major classes of the Company’s assets and liabilities measured at fair value on a recurring basis were as follows (in thousands):

Level 1

Level 2

Level 3

Investments

Measured

at Net

Asset Value

Total

Assets:

Trading securities (a)

i 23,663

—

i 23,663

Partnership interest (b)

—

i 8,391

Total assets

i 23,663

—

i 8,391

i 32,054

Liabilities:

Derivative instruments (c)

—

i 14,668

—

i 14,668

Total liabilities

—

i 14,668

—

i 14,668

/ /

Table of Contents

As of December 31, 2020, the fair values of the major classes of the Company’s assets and liabilities measured at fair value on a recurring basis were as follows (in thousands):

Level 1

Level 2

Level 3

Investments

Measured

at Net

Asset Value

Total

Assets:

Trading securities (a)

i 22,950

—

i 22,950

Partnership interest (b)

—

i 8,665

Total assets

i 22,950

—

i 8,665

i 31,615

Liabilities:

Derivative instruments (c)

—

i 22,617

—

i 22,617

Contingent obligations related to business combinations (d)

—

i 6,793

—

i 6,793

Total liabilities

—

i 22,617

i 6,793

—

i 29,410

(a) Represents the fair value of investments in mutual funds based on quoted market prices that are used to fund the liability associated with the Company’s deferred compensation plan.

(b) The Company has committed to invest $ i 21.5 million as a limited partner in i two private equity funds. The private equity funds invest in opportunities in the healthcare and life sciences industry. As of March 31, 2021, the Company’s remaining unfunded commitment in the private equity funds was $ i 13.9 million. The Company holds minor ownership interests (less than i 3%) in each of the private equity funds and has determined that it does not exercise significant influence over the private equity funds’ operating and finance activities. As the private equity funds do not have readily determinable fair values, the Company has estimated the fair values using each fund’s Net Asset Value, the amount by which the value of all assets exceeds all debt and liabilities, in accordance with ASC Topic 946, Financial Services – Investment Companies.

(d) Represents the fair value of contingent consideration obligations related to business combinations. The fair values of these liabilities are determined based on the Company’s best estimate of the probable timing and amount of settlement.

The following table presents a reconciliation of changes in the carrying amount of contingent obligations classified as Level 3 for the three months ended March 31, 2021 (in thousands):

Balance as of December 31, 2020	$	i 6,793
Additions		i —
Changes in fair value recognized in earnings		( i 597	)
Payments (a)		( i 6,196	)
Balance as of March 31, 2021	$	i —

(a) The Company made payments during the three months ended March 31, 2021 to fully settle the contingent tax-sharing obligation arising from inVentiv Health, Inc.’s 2016 merger with Double Eagle Parent, Inc. (see “Note 16 – Commitments and Contingencies” for further information).

As of March 31, 2021, there were no contingent obligations outstanding. During the three months ended March 31, 2021, there were i i i i i i i i no / / / / / / / transfers of assets or liabilities between Level 1, Level 2, or Level 3 fair value measurements.

Table of Contents

Financial Instruments Subject to Non-Recurring Fair Value Measurements

Certain assets, including goodwill and identifiable intangible assets, are carried on the accompanying condensed consolidated balance sheets at cost and, subsequent to initial recognition, are measured at fair value on a non-recurring basis when certain identified events or changes in circumstances that may have a significant adverse effect on the carrying values of these assets occur. These assets are classified as Level 3 fair value measurements within the fair value hierarchy. Goodwill is tested for impairment annually or more frequently if events or changes in circumstances indicate a triggering event has occurred. Intangible assets are tested for impairment upon the occurrence of certain triggering events. As of March 31, 2021 and December 31, 2020, assets carried on the condensed consolidated balance sheets and not remeasured to fair value on a recurring basis totaled $ i 5.68 billion and $ i 5.71 billion, respectively.

Fair Value Disclosures for Financial Instruments Not Carried at Fair Value

The estimated fair values of the term loans and the Senior Notes are determined based on the price that the Company would have had to pay to settle the liabilities. As these liabilities are not actively traded, they are classified as Level 2 fair value measurements. i The estimated fair values of the Company’s term loans and the Notes were as follows (in thousands):

March 31, 2021

December 31, 2020

Carrying

Value (a)

Estimated

Fair Value

Carrying

Value (a)

Estimated

Fair Value

Term Loan A - tranche one due March 2024

i 173,508

i 173,962

i 183,320

i 183,026

Term Loan A - tranche two due August 2024

i 1,239,681

i 1,243,693

i 1,271,255

i 1,269,213

Term Loan B

i 496,117

i 497,041

i 560,194

i 560,144

3.625% Senior Unsecured Notes due 2029

i 600,000

i 586,500

i 600,000

i 602,412

(a) The carrying value of the term loan debt is shown net of original issue discounts.

7. Restructuring and Other Costs

During the three months ended March 31, 2021, the Company incurred employee severance and benefit costs, facility and lease termination costs, and other costs related to the Company’s restructuring activities. These costs were primarily related to the Company’s ForwardBound margin enhancement initiative.

Restructuring and other costs consisted of the following (in thousands):

	Three Months Ended March 31,
	2021		2020
Employee severance and benefit costs	$	i 6,293	$	i 7,621
Facility and lease termination costs		i 888		i 733
Other costs		i 47		i 366
Total restructuring and other costs	$	i 7,228	$	i 8,720

The Company expects to continue to incur costs related to restructuring of its operations in order to achieve cost savings and the targeted synergies related to its business combinations. However, the timing and the amount of these costs depends on various factors, including, but not limited to, identifying and realizing synergy opportunities and executing the integration of its combined operations. The Company may also continue to incur additional restructuring and other costs during 2021 related to its ForwardBound margin enhancement initiative.

Table of Contents

Accrued Restructuring Liabilities

The following table summarizes activity related to the liabilities associated with restructuring and other costs (in thousands):

Employee

Severance

Costs

Other

Costs

Total

Balance as of December 31, 2020

i 5,830

—

i 5,830

Expenses incurred (a)

i 6,293

i 47

i 6,340

Payments

( i 8,716

)

( i 47

)

( i 8,763

)

Balance as of March 31, 2021

i 3,407

—

i 3,407

(a) The amount of expenses incurred for the three months ended March 31, 2021 excludes $ i 0.9 million of facility lease closure and lease termination costs that are reflected as a reduction of operating lease right-of-use assets on the unaudited condensed consolidated balance sheet under ASC 842.

The Company expects the employee severance costs accrued as of March 31, 2021 will be paid within the next twelve months. Liabilities associated with restructuring and other costs are included in accrued expenses and other long-term liabilities on the accompanying condensed consolidated balance sheets.

8. Shareholders’ Equity

Shares Outstanding

Shares of common stock outstanding were as follows (in thousands):

	Three Months Ended March 31,
	2021			2020
Common stock shares, beginning balance		i 103,935			i 103,866
Repurchases of common stock		( i 600	)		( i 600	)
Issuances of common stock		i 891			i 895
Common stock shares, ending balance		i 104,226			i 104,161

Stock Repurchase Program

On November 17, 2020, the Company’s Board of Directors (the “Board”) authorized the repurchase of up to an aggregate of $ i 300.0 million of the Company’s Class A common stock, par value $ i 0.01 per share, to be executed from time to time in open market transactions effected through a broker at prevailing market prices, in block trades, or through privately negotiated transactions through December 31, 2022 (the “Stock Repurchase Program”). The Stock Repurchase Program took effect on January 1, 2021.

The Stock Repurchase Program does not obligate the Company to repurchase any particular amount of the Company’s common stock and may be modified, extended, suspended, or discontinued at any time. The timing and amount of repurchases will be determined by the Company’s management based on a variety of factors such as the market price of the Company’s common stock, the Company’s corporate cash requirements, and overall market conditions. The Stock Repurchase Program is subject to applicable legal requirements, including federal and state securities laws and applicable Nasdaq rules. The Company may also repurchase shares of its common stock pursuant to a trading plan meeting the requirements of Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, which permits shares of the Company’s common stock to be repurchased when the Company might otherwise be precluded from doing so by law.

Table of Contents

During the three months ended March 31, 2021, the Company repurchased i 600,000 shares of its common stock in a private transaction under the Stock Repurchase Program, for a total purchase price of approximately $ i 44.5 million.

The following table sets forth repurchase activity under the Stock Repurchase Program from inception through March 31, 2021:

Total number of

shares purchased

Average price

paid per share

Approximate

dollar value of

shares purchased

(in thousands)

March 2021

i 600,000

i 74.18

i 44,505

Total

i 600,000

i 44,505

The Company immediately retired all of the repurchased common stock and charged the par value of the shares to common stock. The excess of the repurchase price over the par value was applied on a pro rata basis against additional paid-in capital, with the remainder applied to accumulated deficit.

As of March 31, 2021, the Company had remaining authorization to repurchase up to approximately $ i 255.5 million of shares of its common stock under the Stock Repurchase Program.

9. Earnings Per Share

The following table provides a reconciliation of the numerators and denominators of the basic and diluted earnings per share computations (in thousands, except per share data):

	Three Months Ended March 31,
	2021		2020
Numerator:
Net income	$	i 38,724	$	i 33,574
Denominator:
Basic weighted average common shares outstanding		i 104,274		i 104,265
Effect of dilutive securities:
Stock options and other awards under deferred share-based compensation programs		i 1,183		i 1,377
Diluted weighted average common shares outstanding		i 105,457		i 105,642
Earnings per share:
Basic	$	i 0.37	$	i 0.32
Diluted	$	i 0.37	$	i 0.32

Potential common shares outstanding that are considered anti-dilutive are excluded from the computation of diluted earnings per share. Potential common shares related to stock options and other awards under share-based compensation programs may be determined to be anti-dilutive based on the application of the treasury stock method. Potential common shares are also considered anti-dilutive in periods when the Company incurs a net loss.

The number of potential shares outstanding that were anti-dilutive and therefore excluded from the computation of diluted earnings per share, weighted for the portion of the period they were outstanding, were i 166,166 and i 910,918 for the three months ended March 31, 2021 and 2020, respectively.

Table of Contents

10. Income Taxes

Income Tax Expense

For the three months ended March 31, 2021, the Company recorded income tax expense of $ i 8.3 million, compared to pre-tax income of $ i 47.0 million. Income tax expense for the three months ended March 31, 2021 included a discrete tax benefit of $ i 3.6 million, primarily related to excess tax benefits from share-based compensation. The effective tax rate for the three months ended March 31, 2021, excluding discrete items, varied from the U.S. federal statutory income tax rate of i 21.0% primarily due to foreign income inclusions such as the Global Intangible Low-Taxed Income (“GILTI”) provisions, foreign tax credits, and state and local taxes on U.S. income.

For the three months ended March 31, 2020, the Company recorded income tax expense of $ i 8.2 million, compared to pre-tax income of $ i 41.8 million. Income tax expense for the three months ended March 31, 2020 included $ i 7.1 million of discrete tax benefits primarily related to excess tax benefits from share-based compensation and the benefit from foreign tax credits related to prior years that were quantified or claimed on amended returns during the period. The effective tax rate for the three months ended March 31, 2020, excluding discrete items, varied from the U.S. federal statutory income tax rate of i 21.0% primarily due to foreign income inclusions such as the GILTI provisions, state and local taxes on U.S. income, and research and general business credits.

Unrecognized Tax Benefits

The Company’s gross unrecognized tax benefits, exclusive of associated interest and penalties, were $ i 9.5 million and $ i 9.0 million as of March 31, 2021 and December 31, 2020, respectively. The increase of $ i 0.5 million was primarily due to unrecognized tax benefits in foreign jurisdictions. The Company believes it is reasonably possible that its unrecognized tax benefits may decrease by approximately $ i 0.6 million within the next 12 months as a result of lapses in statutes of limitations.

Tax Returns under Audit

The Company is not currently under any U.S. Federal income tax audits, however, income tax returns are under examination by tax authorities in several state and foreign jurisdictions. The Company’s federal and state tax filings are open to investigations in numerous years due to net operating loss carryforwards. Additionally, the Company currently has an ongoing examination for tax years 2017 and 2018 in the United Kingdom. The United Kingdom is the jurisdiction with the Company’s largest foreign operations. The Company believes that its reserve for uncertain tax positions is adequate to cover existing risks or exposures related to all open tax years.

/ i

11. Revenue from Contracts with Customers

Unsatisfied Performance Obligations

As of March 31, 2021, the total aggregate transaction price allocated to the unsatisfied performance obligations under contracts with contract terms greater than one year and that are not accounted for as a series pursuant to ASC Topic 606,

Table of Contents

Revenue from Contracts with Customers and all the related amendments was $ i 6.93 billion. This amount includes revenue associated with reimbursable out-of-pocket expenses. i The Company expects to recognize revenue over the remaining contract term of the individual projects, with contract terms generally ranging from i one to i five years. The amount of unsatisfied performance obligations is presented net of any constraints and, as a result, is lower than the potential contractual revenue. The contracts excluded due to constraints include contracts that do not commence within a certain period of time or that require the Company to undertake numerous activities to fulfill these performance obligations, including various activities that are outside of the Company’s control. /

Timing of Billing and Performance

During the three months ended March 31, 2021, the Company recognized approximately $ i 349.8 million of revenue that was included in the deferred revenue balance at the beginning of the period. During the three months ended March 31, 2021, approximately $ i 26.3 million of the Company’s revenue recognized was allocated to performance obligations partially satisfied in previous periods, substantially all of which was associated with changes in scope or price for full service clinical studies. The gross and net amounts of revenue recognized solely from changes in estimates were not material.

12. Segment Information

The Company is managed through i two reportable segments: Clinical Solutions and Commercial Solutions. Each reportable segment consists of multiple service offerings that, when combined, create a fully integrated biopharmaceutical services organization. Clinical Solutions offers a variety of services spanning Phases I to IV of clinical development, including full service global studies, as well as individual service offerings such as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with their drug development process. Commercial Solutions provides the pharmaceutical, biotechnology, and healthcare industries with commercialization services, including deployment solutions, communication solutions (public relations, advertising, and medical communications), and consulting services.

The Company’s Chief Operating Decision Maker (“CODM”) reviews segment performance and allocates resources based upon segment revenue and income from operations. Inter-segment revenue is eliminated from the segment reporting presented to the CODM and is not included in the segment revenue presented in the table below. Certain costs are not allocated to the Company’s reportable segments and are reported as general corporate expenses. These costs primarily consist of share-based compensation, general operating expenses associated with the Board and the Company’s senior leadership, finance, investor relations, and internal audit functions, and transaction and integration-related expenses. The Company does not allocate depreciation, amortization, asset impairment charges, or restructuring and other costs to its segments. Prior period segment results have been recast to reflect the transfer of the Kinapse Regulatory and Operations Consulting service lines from Commercial Solutions to Clinical Solutions to align with management reporting in 2021. Additionally, the CODM reviews the Company’s assets on a consolidated basis and does not allocate assets to its reportable segments for purposes of assessing segment performance or allocating resources.

i /

Table of Contents

Information about reportable segment operating results was as follows (in thousands):

	Three Months Ended March 31,
	2021		2020
Revenue:
Clinical Solutions	$	i 937,954	$	i 882,501
Commercial Solutions		i 270,791		i 280,854
Total revenue		i 1,208,745		i 1,163,355
Segment direct costs:
Clinical Solutions		i 716,113		i 682,174
Commercial Solutions		i 220,042		i 233,658
Total segment direct costs		i 936,155		i 915,832
Segment selling, general, and administrative expenses:
Clinical Solutions		i 87,532		i 76,344
Commercial Solutions		i 20,971		i 22,610
Total segment selling, general, and administrative expenses		i 108,503		i 98,954
Segment operating income:
Clinical Solutions		i 134,309		i 123,983
Commercial Solutions		i 29,778		i 24,586
Total segment operating income		i 164,087		i 148,569
Direct costs and operating expenses not allocated to segments:
Share-based compensation included in direct costs		i 9,095		i 8,182
Share-based compensation included in selling, general, and administrative expenses		i 8,258		i 7,816
Corporate selling, general, and administrative expenses		i 20,553		i 18,777
Restructuring and other costs		i 7,228		i 8,720
Depreciation and amortization		i 57,938		i 56,107
Total income from operations	$	i 61,015	$	i 48,967

13. Operations by Geographic Location

The following table summarizes total revenue by geographic area (in thousands, all intercompany transactions have been eliminated):

	Three Months Ended March 31,
	2021		2020
Revenue:
North America (a)	$	i 739,001	$	i 753,045
Europe, Middle East, and Africa		i 316,176		i 268,022
Asia-Pacific		i 126,457		i 117,053
Latin America		i 27,111		i 25,235
Total revenue	$	i 1,208,745	$	i 1,163,355

(a) Revenue for the North America region includes revenue attributable to the United States of $ i 693.9 million and $ i 713.4 million, or i 57.4% and i 61.3% of total revenue, for the three months ended March 31, 2021 and 2020, respectively. No other country represented more than 10% of total revenue for any period.

/ /

Table of Contents

The following table summarizes long-lived assets by geographic area (in thousands, all intercompany transactions have been eliminated):

	March 31, 2021		December 31, 2020
Property and equipment, net:
North America (a)	$	i 151,611	$	i 161,531
Europe, Middle East, and Africa		i 36,508		i 38,745
Asia-Pacific		i 9,392		i 11,167
Latin America		i 5,107		i 4,757
Total property and equipment, net	$	i 202,618	$	i 216,200

(a) Long-lived assets for the North America region include property and equipment, net attributable to the United States of $ i 145.8 million and $ i 156.0 million as of March 31, 2021 and December 31, 2020, respectively.

/ i

14. Concentration of Credit Risk

Financial assets that subject the Company to credit risk primarily consist of cash and cash equivalents, accounts receivable, and unbilled services (including contract assets). The Company’s cash and cash equivalents consist principally of cash and are maintained at several financial institutions with reputable credit ratings. The Company maintains cash depository accounts with several financial institutions worldwide and is exposed to credit risk related to the potential inability to access liquidity in financial institutions where its cash and cash equivalents are concentrated. The Company has not historically incurred any losses with respect to these balances and believes that they bear minimal credit risk.

As of March 31, 2021 and December 31, 2020, the majority of the Company’s cash and cash equivalents were held within the United States.

No single customer accounted for greater than i i 10 / % of the Company’s revenue for the three months ended March 31, 2021 and 2020.

As of March 31, 2021 and December 31, 2020, no single customer accounted for greater than i i 10 / % of the Company’s accounts receivable and unbilled services (including contract assets) balances.

/ i

15. Related-Party Transactions

For the three months ended March 31, 2021, the Company had revenue of $ i 0.3 million and, as of March 31, 2021, receivables of $ i 0.3 million from i one customer whose board of directors included a member who was also a member of the Company’s Board.

There were no material related party transactions for the three months ended March 31, 2020.

/ i

16. Commitments and Contingencies

Legal Proceedings

The Company is involved in various claims and legal actions arising in the ordinary course of business. The Company accrues a liability when a loss is considered probable and the amount can be reasonably estimated. When a material loss contingency is reasonably possible but not probable, the Company does not record a liability, but instead discloses the nature and the amount of the claim, and an estimate of the loss or range of loss, if such an estimate can be made. Legal fees are expensed as incurred. In the opinion of management, the outcome of any existing claims and legal or regulatory proceedings, other than the specific matters described below, if decided adversely, is not expected to have a material adverse effect on the Company's business, financial condition, results of operations, or cash flows.

Table of Contents

On December 1, 2017, the first of i two virtually identical actions alleging federal securities law claims was filed against the Company and certain of its officers on behalf of a putative class of its shareholders. The first action, captioned Bermudez v. INC Research, Inc., et al, No. 17-09457 (S.D.N.Y.) in the Southern District of New York, names as defendants the Company, Michael Bell, Alistair Macdonald, Michael Gilbertini, and Gregory S. Rush (the “Bermudez action”), and the second action, Vaitkuvienë v. Syneos Health, Inc., et al, No. 18-0029 (E.D.N.C.) in the Eastern District of North Carolina, filed on January 25, 2018 (the “Vaitkuvienë action”), names as defendants the Company, Alistair Macdonald, and Gregory S. Rush (the “Initial Defendants”). Both complaints allege similar claims under Section 10(b) and Section 20(a) of the Securities Exchange Act of 1934 on behalf of a putative class of purchasers of the Company’s common stock between May 10, 2017 and November 8, 2017 (for the Vaitkuvienë action) and November 9, 2017 (for the Bermudez action). The complaints allege that the Company published inaccurate or incomplete information regarding, among other things, the financial performance and business outlook for inVentiv’s business prior to the 2017 merger (the “Merger”) with Double Eagle Parent, Inc. (“inVentiv”), the parent company of inVentiv Health, Inc., and with respect to the combined company following the Merger. On January 30, 2018, i two alleged shareholders separately filed motions seeking to be appointed lead plaintiff and approving the selection of lead counsel. On March 30, 2018, Plaintiff in the Bermudez action filed a notice of voluntary dismissal of the Bermudez action, without prejudice, and as to all defendants. On May 29, 2018, the Court in the Vaitkuvienë action appointed the San Antonio Fire & Police Pension Fund and El Paso Firemen & Policemen’s Pension Fund as Lead Plaintiffs and, on June 7, 2018, the Court entered a schedule providing for, among other things, Lead Plaintiffs to file an amended complaint by July 23, 2018 (later extended to July 30, 2018). Lead Plaintiffs filed their amended complaint on July 30, 2018, which also includes a claim against the Initial Defendants, as well as each member of the board of directors at the time of the INC Research - inVentiv Health merger vote in July 2017 (the “Defendants”), contending that the inVentiv merger proxy was misleading under Section 14(a) of the Act. Lead Plaintiffs seek, among other things, orders (i) declaring that the lawsuit is a proper class action and (ii) awarding compensatory damages in an amount to be proven at trial, including interest thereon, and reasonable costs and expenses incurred in this action, including attorneys’ fees and expert fees, to Lead Plaintiffs and other class members. Defendants filed a Motion to Dismiss Plaintiffs’ Amended Complaint on September 20, 2018. Lead Plaintiffs filed a Response in Opposition to such motion on November 21, 2018, and Defendants filed a Reply to such response on December 5, 2018. The District Court referred the Motion to Dismiss to a magistrate judge for a report and recommendation. On September 26, 2019, the magistrate judge stayed the action and, on August 7, 2020, the magistrate judge lifted the stay. Also on August 7, 2020, the magistrate judge issued a report (the “Magistrate Report”) recommending to the District Court that Defendants’ Motion to Dismiss be denied. On September 4, 2020, Defendants filed written objections to the Magistrate Report, requesting that the District Court grant the Motion to Dismiss. Lead Plaintiffs filed a Response in Opposition to such objections on October 2, 2020. The Company and the other defendants deny the allegations in these complaints and intend to defend vigorously against these claims.

The Company is presently unable to predict the duration, scope, or result of the foregoing putative class actions, or any other related lawsuit. As such, the Company is presently unable to develop a reasonable estimate of a possible loss or range of losses, if any, related to these matters. While the Company intends to defend the putative class action litigation vigorously, the outcome of such litigation or any other litigation is necessarily uncertain. The Company could be forced to expend significant resources in the defense of these lawsuits or future ones, and it may not prevail. As such, these matters could have a material adverse effect on the Company's business, annual, or interim results of operations, cash flows, or its financial condition.

Table of Contents

Assumed Contingent Tax-Sharing Obligations

As a result of the Merger, the Company assumed contingent tax-sharing obligations arising from inVentiv Health, Inc.’s 2016 merger with Double Eagle Parent, Inc. During the three months ended March 31, 2021, the Company made payments of $ i 6.2 million to fully settle this outstanding obligation. As of December 31, 2020, the estimated fair value of the assumed contingent tax-sharing obligations was $ i 6.8 million.

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

Forward Looking Statements

You should read the following discussion and analysis of our financial condition and results of operations in conjunction with our unaudited condensed consolidated financial statements and the notes thereto included elsewhere in this Quarterly Report on Form 10-Q, and with our audited consolidated financial statements and the notes thereto included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020.

In addition to historical condensed consolidated financial information, this Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that reflect, among other things, our current expectations and anticipated results of operations, all of which are subject to known and unknown risks, uncertainties, and other factors that may cause our actual results, performance or achievements, market trends, or industry results to differ materially from those expressed or implied by such forward-looking statements. Therefore, any statements contained herein that are not statements of historical fact may be forward-looking statements and should be evaluated as such, including our business strategy, the future impact of the COVID-19 pandemic on our business, financial results, and financial condition, and planned capital expenditures. Without limiting the foregoing, the words “anticipates,” “believes,” “can,” “continue,” “could,” “estimates,” “expects,” “intends,” “may,” “might,” “plans,” “projects,” “should,” “would,” “targets,” “will” and the negative thereof and similar words and expressions are intended to identify forward-looking statements. Unless legally required, we assume no obligation to update any such forward-looking information to reflect actual results or changes in the factors affecting such forward-looking information.

We caution you that any such forward-looking statements are further qualified by important factors that could cause our actual operating results to differ materially from those in the forward-looking statements, including without limitation, regional, national, or global political, economic, business, competitive, market, and regulatory conditions and the following: risks associated with the COVID-19 pandemic; our potential failure to generate a large number of new business awards and the risk of delay, termination, reduction in scope, or failure to go to contract of our business awards; our potential failure to convert backlog to revenue; fluctuations in our operating results and effective income tax rate; the impact of potentially underpricing our contracts, overrunning our cost estimates, or failing to receive approval for or experiencing delays with documentation of change orders; cyber-security and other risks associated with our information systems infrastructure; changes and costs of compliance with regulations related to data privacy; concentration of our customers or therapeutic areas; the risks associated with doing business internationally; risks related to the impact of the U.K.’s withdrawal from the European Union; challenges by tax authorities of our intercompany transfer pricing policies; our potential failure to successfully increase our market share, grow our business, and execute our growth strategies; our ability to effectively upgrade our information systems; our failure to perform our services in accordance with contractual requirements, regulatory standards, and ethical considerations; risks related to the management of clinical trials; risks related to investments in our customers’ businesses or drugs and our related commercial rights strategies; the need to hire, develop, and retain key personnel; the impact of unfavorable economic conditions, including the uncertain international economic environment, changes in exchange rates; effective income tax rate fluctuations; our ability to protect our intellectual property; risks related to our acquisition strategy, including our ability to realize synergies; our relationships with customers who are in competition with each other; any failure to realize the full value of our goodwill and intangible assets; risks related to restructuring; our compliance with anti-corruption and anti-bribery laws; our dependence on third parties; potential employment liability; our ability to utilize net operating loss carryforwards and other tax attributes; downgrades of our credit ratings; competition in the biopharmaceutical services industry; outsourcing trends and changes in aggregate spending and research and development budgets; the impact of, including changes in, government regulations and healthcare reform; our ability to keep pace with rapid technological change; the cost of and our ability to service our substantial indebtedness; and other risks related to ownership of our common stock. For a

Table of Contents

further discussion of the risks relating to our business, refer to “Risk Factors” in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended December 31, 2020.

Overview of Our Business and Services

We are a leading global biopharmaceutical solutions organization providing a full suite of clinical and commercial services to customers in the biopharmaceutical, biotechnology, and healthcare industries. We offer both stand-alone and integrated biopharmaceutical product development solutions ranging from Early Phase (Phase I) clinical trials to the full commercialization of biopharmaceutical products, with the goal of increasing the likelihood of regulatory approval and commercial success.

Our operations are divided into two reportable segments, Clinical Solutions and Commercial Solutions. Our Clinical Solutions segment offers a variety of services spanning Phases I to IV of clinical development, including full service global studies and real world evidence programs, as well as individual service offerings such as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with their drug development process. Our Commercial Solutions segment provides commercialization services, including deployment solutions, communication solutions (public relations, advertising, and medical communications), and consulting services. We integrate our clinical and commercial capabilities into customized solutions by sharing knowledge, data, and insights through our Biopharmaceutical Acceleration Model. This collaboration across the development and commercialization continuum facilitates unique insights into patient populations, therapeutic environments, product timelines, and the competitive landscape. For further discussion, refer to “Business” in Part I, Item 1 of our Annual Report on Form 10-K for the fiscal year ended December 31, 2020.

Prior period segment results have been recast to reflect the transfer of the Kinapse Regulatory and Operations Consulting service lines from Commercial Solutions to Clinical Solutions to align with management reporting in 2021.

COVID-19 Pandemic

On March 11, 2020, the World Health Organization designated the outbreak of the novel strain of coronavirus that causes the disease known as COVID-19 as a global pandemic. Governments and businesses around the world have taken unprecedented actions to mitigate the spread of COVID-19, including, but not limited to, shelter-in-place orders, quarantines, significant restrictions on travel, social distancing practices as well as restrictions that prohibit many employees from going to work in person. As a result, we experienced significant impacts to our business and results of operations from COVID-19 during 2020 and for the three months ended March 31, 2021. While certain governments have eased restrictions, the pandemic continues to be disruptive to our business. The pandemic and associated economic impacts are expected to continue to significantly impact our future financial condition, results of operations and cash flows.

For a further discussion of this and other risks relating to our business, refer to “Risk Factors” in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended December 31, 2020.

Table of Contents

New Business Awards and Backlog

We add new business awards to backlog when we enter into a contract or when we receive a written commitment from the customer selecting us as a service provider, provided that:

•

collection of the award value is probable;

•

the project or projects are expected to commence within a certain period of time from the end of the quarter in which the award was granted;

•

project contingencies such as the outcome of other clinical trials, funding approvals, or other events, are not anticipated to prevent the project or projects from commencing in accordance with the expected timeline;

•

the customer has entered or intends to enter into a comprehensive contract as soon as practicable; and

•

for awards related to deployment solutions and functional service provider offerings, a maximum of twelve months of services are included in the award value.

In addition, we continually evaluate our backlog to determine if any of the previously awarded work is no longer expected to be performed, regardless of whether we have received formal cancellation notice from the customer. If we determine that any previously awarded work is no longer probable of being performed, we remove the value from our backlog based on the risk of cancellation. We recognize revenue from these awards as services are performed, provided we have received proper authorization from the customer.

We report new business awards for our Clinical Solutions and Commercial Solutions segments on a trailing twelve months (“TTM”) basis. Our total backlog represents backlog for our Clinical Solutions segment and the deployment solutions offering within our Commercial Solutions segment. We do not report backlog for the remaining service offerings in the Commercial Solutions segment.

Backlog

Our backlog consists of anticipated future revenue from business awards that either have not started, or that are in process and have not been completed. Our backlog also reflects any cancellation or adjustment activity related to these awards. The average duration of our contracts will fluctuate from period to period based on the contracts comprising our backlog at any given time. The majority of our contracts contain early termination provisions that typically require notice periods ranging from 30 to 90 days.

Our backlog as of March 31 was as follows (in millions):

	2021		2020		Change
Clinical Solutions	$	10,509.9	$	8,578.9	$	1,931.0	22.5	%
Commercial Solutions - Deployment Solutions		708.1		658.1		50.0	7.6	%
Total backlog	$	11,218.0	$	9,237.0	$	1,981.0	21.4	%

We expect approximately $3.48 billion of our backlog as of March 31, 2021 will be recognized as revenue during the remainder of 2021. We adjust the amount of our backlog each quarter for the effects of fluctuations in foreign currency exchange rates.

Table of Contents

Net New Business Awards

New business awards, net of cancellations, for the TTM periods ended March 31 were as follows (in millions):

	2021		2020
Clinical Solutions	$	4,720.1	$	4,482.2
Commercial Solutions		1,160.0		1,242.5
Total net new business awards	$	5,880.1	$	5,724.7

New business awards have varied and may continue to vary significantly from quarter to quarter. Fluctuations in our net new business award levels often result from the fact that we may receive a small number of relatively large orders in any given reporting period. Because of these large orders, our backlog and net new business awards in a reporting period may reach levels that are not sustainable in subsequent reporting periods.

We believe that our backlog and net new business awards might not be consistent indicators of future revenue because they have been, and likely will continue to be, affected by a number of factors, including the variable size and duration of projects, many of which are performed over several years, and changes to the scope of work during the course of projects. Additionally, projects may be canceled or delayed by the customer or regulatory authorities. Net new business awards and backlog have been and we expect will continue to be affected by the broad effects of the COVID-19 pandemic on the global economy and major financial markets, as well as various other risks and uncertainties detailed in Part I, Item 1A “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020. We generally do not have a contractual right to the full amount of the awards reflected in our backlog. If a customer cancels an award, we might be reimbursed for the costs we have incurred. As we increasingly compete for and enter into large contracts that are more global in nature, we expect that the rate at which our backlog and net new business awards convert into revenue is likely to decrease, and the duration of projects and the period over which related revenue is recognized to lengthen. For more information about risks related to our backlog see Part I, Item 1A “Risk Factors - Risks Related to Our Business - Our backlog might not be indicative of our future revenues, and we might not realize all of the anticipated future revenue reflected in our backlog.” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020.

Results of Operations

The following table sets forth amounts from our unaudited condensed consolidated statements of income along with dollar and percentage changes (in thousands, except percentages):

	Three Months Ended March 31,
	2021		2020		Change
Revenue	$	1,208,745	$	1,163,355	$	45,390		3.9	%
Costs and operating expenses:
Direct costs (exclusive of depreciation and amortization)		945,250		924,014		21,236		2.3	%
Selling, general, and administrative expenses		137,314		125,547		11,767		9.4	%
Restructuring and other costs		7,228		8,720		(1,492	)	(17.1	)%
Depreciation and amortization		57,938		56,107		1,831		3.3	%
Total operating expenses		1,147,730		1,114,388		33,342		3.0	%
Income from operations		61,015		48,967		12,048		24.6	%
Total other expense, net		14,004		7,192		6,812		94.7	%
Income before provision for income taxes		47,011		41,775		5,236		12.5	%
Income tax expense		8,287		8,201		86		1.0	%
Net income	$	38,724	$	33,574	$	5,150		15.3	%

Table of Contents

Revenue

For the three months ended March 31, 2021, our revenue increased by $45.4 million, or 3.9%, to $1,208.7 million from $1,163.4 million for the three months ended March 31, 2020. The increase was primarily driven by growth in our Clinical Solutions segment, which was partially offset by a decrease in our Commercial Solutions segment, as discussed below.

No single customer accounted for greater than 10% of our total consolidated revenue for the three months ended March 31, 2021 and 2020. Revenue from our top five customers accounted for approximately 23% and 21% of revenue for the three months ended March 31, 2021 and 2020, respectively.

Revenue for each of our segments was as follows (dollars in thousands):

	Three Months Ended March 31,
	2021		% of total			2020		% of total			Change
Clinical Solutions	$	937,954		77.6	%	$	882,501		75.9	%	$	55,453		6.3	%
Commercial Solutions		270,791		22.4	%		280,854		24.1	%		(10,063	)	(3.6	)%
Total revenue	$	1,208,745				$	1,163,355				$	45,390		3.9	%

Clinical Solutions

For the three months ended March 31, 2021, revenue attributable to our Clinical Solutions segment increased compared to the same period in the prior year primarily due to the acquisitions of SHCR Holdings Corporation (“Synteract”) and Illingworth Research Group™ (“Illingworth Research”) that were completed in the fourth quarter of 2020, and increased project start-ups. The revenue increase was partially offset by decreases from the divestiture of our contingent staffing business in the second quarter of 2020 and a decline in reimbursable out-of-pocket expenses due to the impacts of the COVID-19 pandemic. For the three months ended March 31, 2021, revenue was positively impacted by $9.6 million from foreign currency exchange rates fluctuations compared to the same period in the prior year.

Although we are aggressively managing our response to the COVID-19 pandemic, we expect that the COVID-19 pandemic will continue to negatively impact our Clinical Solutions revenue throughout 2021, depending on the continuation of the pandemic. At this time, we believe that the ongoing impacts to revenue in our Clinical Solutions segment will be similar in nature to those experienced in 2020 with the most significant being the trend of more remote monitoring visits and delayed patient enrollment, resulting in lower reimbursable out-of-pocket expenses and related revenue as the recovery continues. We expect a moderate increase in the use of remote monitoring from pre-COVID-19 levels, although below levels necessitated in 2020.

Commercial Solutions

For the three months ended March 31, 2021, revenue attributable to our Commercial Solutions segment decreased compared to the same period in the prior year primarily due to a decline in reimbursable out-of-pocket expenses due to the impacts of the COVID-19 pandemic and the divestiture of our medication adherence business in the fourth quarter of 2020. The decrease was partially offset by an increase in revenue from our consulting service offerings.

Table of Contents

Although we are aggressively managing our response to the COVID-19 pandemic, we expect that the COVID-19 pandemic will continue to negatively impact our Commercial Solutions revenue throughout 2021, depending on the continuation of the pandemic. At this time, we believe that the ongoing impacts to revenue in our Commercial Solutions segment will be temporary and relate to delayed decision-making related to new business awards, delays or cancellations of existing projects, declines in field team visits to healthcare providers, investigator meetings, and travel disruptions, similar to those experienced in 2020, resulting in lower reimbursable out-of-pocket expenses and related revenue as the recovery continues.

Direct Costs

Direct costs consist principally of compensation expense and benefits associated with our employees and other employee-related costs, and reimbursable out-of-pocket expenses directly related to delivering on our projects. While we have some ability to manage the majority of these costs relative to the amount of contracted services we have during any given period, direct costs as a percentage of revenue can vary from period to period. Such fluctuations are due to a variety of factors, including, among others: (i) the level of staff utilization on our projects; (ii) adjustments to the timing of work on specific customer contracts; (iii) the experience mix of personnel assigned to projects; (iv) the service mix and pricing of our contracts; and (v) the timing of the incurrence of reimbursable out-of-pocket expenses. As a result of the COVID-19 pandemic, we have experienced reduced travel and other reimbursable out-of-pocket expenses related to lower physical monitoring visits for Clinical Solutions, as well as fewer field team visits to healthcare providers and investigator meetings for Commercial Solutions.

Direct costs consisted of the following (dollars in thousands):

	Three Months Ended March 31,
	2021			2020			Change
Direct costs (exclusive of depreciation and amortization)	$	945,250		$	924,014		$	21,236	2.3	%
% of revenue		78.2	%		79.4	%
Gross margin %		21.8	%		20.6	%

For the three months ended March 31, 2021, our direct costs increased by $21.2 million, or 2.3%, compared to the three months ended March 31, 2020, primarily driven by impacts from the acquisitions that were completed in the fourth quarter of 2020, partially offset by decreases from divestitures and lower reimbursable out-of-pocket expenses.

Clinical Solutions

Direct costs for our Clinical Solutions segment, excluding share-based compensation expense, were as follows (dollars in thousands):

	Three Months Ended March 31,
	2021			2020			Change
Direct costs	$	716,113		$	682,174		$	33,939	5.0	%
% of segment revenue		76.3	%		77.3	%
Segment gross margin %		23.7	%		22.7	%

Table of Contents

For the three months ended March 31, 2021, our Clinical Solutions segment direct costs increased by $33.9 million, or 5.0%, compared to the three months ended March 31, 2020. This increase was primarily due to the acquisitions that were completed in the fourth quarter of 2020, higher compensation-related expenses due to higher billable headcount, and the negative impact of foreign exchange rate fluctuations. This increase was partially offset by the divestiture of our contingent staffing business in the second quarter of 2020, a decline in reimbursable out-of-pocket expense due to the impacts of the COVID-19 pandemic, and positive impacts from our ForwardBound margin enhancement initiative.

Gross margins for our Clinical Solutions segment were 23.7% and 22.7% for the three months ended March 31, 2021 and 2020, respectively. Gross margin was higher during the current year period as compared to the same period in the prior year primarily due to positive impacts from our ForwardBound margin enhancement initiative and favorable revenue mix, partially offset by the negative impact of foreign exchange rate fluctuations.

Commercial Solutions

Direct costs for our Commercial Solutions segment, excluding share-based compensation expense, were as follows (dollars in thousands):

	Three Months Ended March 31,
	2021			2020			Change
Direct costs	$	220,042		$	233,658		$	(13,616	)	(5.8	)%
% of segment revenue		81.3	%		83.2	%
Segment gross margin %		18.7	%		16.8	%

For the three months ended March 31, 2021, our Commercial Solutions segment direct costs decreased by $13.6 million, or 5.8%, compared to the three months ended March 31, 2020. This decrease was primarily related to a decline in reimbursable out-of-pocket expenses due to the impacts of the COVID-19 pandemic and the divestiture of our medication adherence business in the fourth quarter of 2020.

Gross margins for our Commercial Solutions segment were 18.7% and 16.8% for the three months ended March 31, 2021 and 2020, respectively. Gross margin was higher during the current year period as compared to the same period in the prior year primarily due to favorable revenue mix and lower reimbursable out-of-pocket expenses.

Selling, General, and Administrative Expenses

Selling, general, and administrative expenses were as follows (dollars in thousands):

	Three Months Ended March 31,
	2021			2020			Change
Selling, general, and administrative expenses	$	137,314		$	125,547		$	11,767	9.4	%
% of total revenue		11.4	%		10.8	%

Selling, general, and administrative expenses for the three months ended March 31, 2021 increased compared to the same period in 2020 primarily due to the acquisitions that were completed in the fourth quarter of 2020 and the negative impact of foreign exchange rate fluctuations, partially offset by positive impacts from our ForwardBound margin enhancement initiative. Transaction and integration-related expenses are no longer reported separately and are included in selling, general, and administrative expenses.

Table of Contents

Restructuring and Other Costs

Restructuring and other costs were $7.2 million and $8.7 million for the three months ended March 31, 2021 and 2020, respectively. The costs incurred during the three months ended March 31, 2021 were primarily related to our ForwardBound margin enhancement initiative as we continue the ongoing evaluations of our workforce and facilities infrastructure needs in an effort to optimize our resources.

Restructuring and other costs consisted of the following (in thousands):

	Three Months Ended March 31,
	2021		2020
Employee severance and benefit costs	$	6,293	$	7,621
Facility and lease termination costs		888		733
Other costs		47		366
Total restructuring and other costs	$	7,228	$	8,720

We expect to continue to incur costs related to the restructuring of our operations in order to achieve cost savings and the targeted synergies related to our business combinations. However, the timing and the amount of these costs depends on various factors, including, but not limited to, identifying and realizing synergy opportunities and executing the integration of our combined operations. We may also continue to incur additional restructuring and other costs during 2021 related to our ForwardBound margin enhancement initiative.

Depreciation and Amortization Expense

Total depreciation and amortization expense was $57.9 million and $56.1 million for the three months ended March 31, 2021 and 2020, respectively. The increase in total depreciation and amortization expense in the current year compared to the prior year was primarily due to depreciation and amortization from the acquisitions that were completed in the fourth quarter of 2020, partially offset by a decrease due to fully amortized intangible assets from prior acquisitions.

Total Other Expense, Net

Total other expense, net consisted of the following (dollars in thousands):

	Three Months Ended March 31,
	2021			2020			Change
Interest income	$	(71	)	$	(336	)	$	265		(78.9	)%
Interest expense		23,328			26,458			(3,130	)	(11.8	)%
Loss on extinguishment of debt		603			—			603		100.0	%
Other income, net		(9,856	)		(18,930	)		9,074		(47.9	)%
Total other expense, net	$	14,004		$	7,192		$	6,812		94.7	%

Total other expense, net was $14.0 million and $7.2 million for the three months ended March 31, 2021 and 2020, respectively. The decrease in interest expense was primarily due to reductions in our higher interest rate debt as a result of debt prepayments and refinancing transactions as well as lower interest rates on our variable interest rate debt. Other income, net primarily consists of foreign currency gains and losses that result from exchange rate fluctuations on our monetary asset balances denominated in currencies other than our functional currency.

Table of Contents

Income Tax Expense

For the three months ended March 31, 2021, we recorded income tax expense of $8.3 million, compared to pre-tax income of $47.0 million. Income tax expense for the three months ended March 31, 2021 included a discrete tax benefit of $3.6 million, primarily related to excess tax benefits from share-based compensation. The effective tax rate for the three months ended March 31, 2021, excluding discrete items, varied from the U.S. federal statutory income tax rate of 21.0% primarily due to foreign income inclusions such as the Global Intangible Low-Taxed Income (“GILTI”) provisions, foreign tax credits, and state and local taxes on U.S. income.

For the three months ended March 31, 2020, we recorded income tax expense of $8.2 million, compared to pre-tax income of $41.8 million. The effective tax rate for the three months ended March 31, 2020 varied from the U.S. federal statutory income tax rate of 21.0% primarily due to foreign income inclusions such as the GILTI provisions, state and local taxes on U.S. income, and research and general business credits.

We currently maintain a valuation allowance against a portion of our state deferred tax assets and a portion of our foreign deferred tax assets as of March 31, 2021. We intend to continue to maintain a valuation allowance on these deferred tax assets until there is sufficient evidence to support the reversal of all or some portion of these allowances.

Liquidity and Capital Resources

Key measures of our liquidity were as follows (in thousands):

	March 31, 2021		December 31, 2020
Balance sheet statistics:
Cash and cash equivalents	$	264,424	$	271,901
Restricted cash		265		272
Working capital (excluding restricted cash)		141,828		160,409

As of March 31, 2021, we had $264.7 million of cash, cash equivalents, and restricted cash. As of March 31, 2021, the majority of our cash, cash equivalents, and restricted cash was held within the United States. In addition, we had $583.9 million (net of $16.1 million in outstanding letters of credit (“LOCs”)) available for borrowing under our revolving credit facility (the “Revolver”), of which $133.9 million was available for LOCs.

We have historically funded our operations and growth, including acquisitions, primarily with our working capital, cash flow from operations, and funds available through various borrowing arrangements. Our principal liquidity requirements are to fund our debt service obligations, capital expenditures, expansion of service offerings, possible acquisitions, integration and restructuring costs, geographic expansion, stock repurchases, working capital, and other general corporate expenses. Cash flow from operations also could be affected by various risks and uncertainties, including, but not limited to, the effects of the COVID-19 pandemic on the global economy and major financial markets, as well as other risks detailed in Part I, Item 1A “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020. Based on past performance and current expectations, we believe our cash and cash equivalents, cash generated from operations, and funds available under the Revolver will be sufficient to meet our working capital needs, capital expenditures, scheduled debt and interest payments, income tax obligations, and other currently anticipated liquidity requirements for at least the next 12 months.

Table of Contents

Indebtedness

As of March 31, 2021, we had approximately $2.92 billion of total principal indebtedness (including $44.6 million in finance lease obligations), consisting of $1.91 billion in term loan debt, $600.0 million of 3.625% senior notes (the “Notes”), and $365.0 million in borrowings against our accounts receivable financing agreement. Approximately $810.8 million of our indebtedness (excluding finance leases) was subject to variable interest rates.

3.625% Senior Notes Due 2029

On November 24, 2020, we completed the issuance and sale of $600.0 million aggregate principal amount of the Notes. The Notes were issued pursuant to an indenture (the “Indenture”), which provides, among other things, that the Notes are senior unsecured obligations of us and are guaranteed, jointly and severally, on a senior unsecured basis, by certain of our subsidiaries.

We may redeem some or all of the Notes at any time prior to January 15, 2024 at a redemption price equal to 100% of the aggregate principal amount of the Notes to be redeemed plus a “make-whole” premium and accrued and unpaid interest. In addition, prior to July 15, 2023, we may redeem up to 40% of the original principal amount of the Notes with proceeds of certain equity offerings at a redemption price equal to 103.625% of the aggregate principal amount of such Notes plus accrued and unpaid interest. On or after January 15, 2024, we may redeem some or all of the Notes at the redemption prices set forth in the Indenture plus accrued and unpaid interest. The Indenture contains covenants that limit the ability of us and our restricted subsidiaries to, among other things, (1) incur additional liens, (2) engage in certain sale and leaseback transactions, and (3) conduct mergers, consolidations, or asset sales. These covenants are subject to exceptions and qualifications set forth in the Indenture.

If we sell certain of our assets or experience specific kinds of changes of control, we are required to offer to repurchase the Notes at a repurchase price equal to (1) par plus any accrued and unpaid interest in the case of an asset sale or (2) 101% of the aggregate principal amount thereof plus any accrued and unpaid interest in the case of a change of control.

Credit Agreement

We are party to a credit agreement (as amended, the “Credit Agreement”) that includes a $1.55 billion Term Loan A facility (“Term Loan A”) that has two tranches, tranche one that matures on March 26, 2024 and tranche two that matures on August 1, 2024, a $1.60 billion Term Loan B facility (“Term Loan B”) that matures on August 1, 2024, and a $600.0 million Revolver that matures on August 1, 2024. The Revolver includes LOCs with a sublimit of $150.0 million.

In February 2021, as a result of our First Lien Leverage Ratio (as defined in the Credit Agreement) being less than or equal to 2.5x, the Adjusted Eurocurrency Rate Spread (as defined in the Credit Agreement) on Term Loan A and the Revolver decreased from 1.50% to 1.25%.

During the three months ended March 31, 2021, we made $41.8 million and $64.1 million of voluntary prepayments against Term Loan A and Term Loan B, respectively, which were applied to future principal payments. As a result of these and previous voluntary prepayments, we are not required to make a mandatory payment against the principal balance of Term Loan A until October 2022 and Term Loan B until maturity in August 2024.

Table of Contents

Our ability to make payments on our indebtedness and to fund planned capital expenditures and necessary working capital will depend on our ability to generate cash in the future. Our ability to meet our cash needs through cash flows from operations will depend on the demand for our services, as well as general economic, financial, competitive, and other factors, many of which are beyond our control, including the broad effects of the COVID-19 pandemic on the global economy and major financial markets. Our business may not generate cash flow in an amount sufficient to enable us to pay the principal of, or interest on, our indebtedness, or to fund our other liquidity needs, including working capital, capital expenditures, acquisitions, investments, and other general corporate requirements. If we cannot fund our liquidity needs, we will have to take actions such as reducing or delaying capital expenditures, acquisitions or investments, selling assets, restructuring or refinancing our debt, reducing the scope of our operations and growth plans, or seeking additional capital. We cannot assure you that any of these remedies could, if necessary, be affected on commercially reasonable terms, or at all, or that they would permit us to meet our scheduled debt service obligations. The Credit Agreement contains covenant restrictions that limit our ability to direct the use of proceeds from any disposition of assets and, as a result, we may not be allowed to use the proceeds from any such dispositions to satisfy all current debt service obligations.

Debt Covenants

Our Credit Agreement contains usual and customary restrictive covenants. Our Credit Agreement requires us to maintain a maximum First Lien Leverage Ratio (as defined in the Credit Agreement) of no more than 4.5 to 1.0 as of the last day of each fiscal quarter from and after March 31, 2020.

The Indenture also contains customary events of default, including (1) failure to make required payments, (2) failure to comply with certain covenants, (3) failure to pay certain other indebtedness, (4) certain events of bankruptcy and insolvency, and (5) failure to pay certain judgments. An event of default under the Indenture allows either the Trustee or the holders of at least 25% in aggregate principal amount of the Notes, as applicable, issued under such Indenture, to accelerate the amounts due under the Notes, or in the case of a bankruptcy or insolvency, will automatically cause the acceleration of the amounts due under the Notes.

As of March 31, 2021, we were in compliance with all applicable debt covenants.

Revolver and Letters of Credit

The Revolver includes LOCs with a sublimit of $150.0 million. As of March 31, 2021, there were no outstanding Revolver borrowings and $16.1 million of LOCs outstanding, leaving $583.9 million of available borrowings under the Revolver, including $133.9 million available for LOCs.

Accounts Receivable Financing Agreement

We have an accounts receivable financing agreement (as amended) with a termination date of October 3, 2022, unless terminated earlier pursuant to its terms. On January 28, 2021, we amended our accounts receivable financing agreement to increase the amount we can borrow from $300.0 million to $365.0 million, and drew down the additional $65.0 million to partially fund the Term Loan A and Term Loan B voluntary prepayments. Accordingly, there was no incremental impact on the outstanding principal of our debt. As of March 31, 2021, we had $365.0 million of outstanding borrowings under this agreement with no remaining borrowing capacity available.

Table of Contents

Interest Rates

We have entered into various interest rate swaps to mitigate our exposure to changes in interest rates on our term loans. As of March 31, 2021, the percentage of our total principal debt (excluding finance leases) that is subject to fixed interest rates was approximately 72%. Each quarter-point increase or decrease in the applicable floating interest rate at March 31, 2021 would change our annual interest expense by approximately $2.0 million.

Stock Repurchase Program

On November 17, 2020, our Board authorized the repurchase of up to an aggregate of $300.0 million of our Class A common stock, par value $0.01 per share, to be executed from time to time in open market transactions effected through a broker at prevailing market prices, in block trades, or through privately negotiated transactions through December 31, 2022 (the “Stock Repurchase Program”). The Stock Repurchase Program took effect on January 1, 2021. Share repurchases are funded primarily with our working capital, cash flow from operations, and funds available through various borrowing arrangements.

The Stock Repurchase Program does not obligate us to repurchase any particular amount of our common stock and may be modified, extended, suspended, or discontinued at any time. The timing and amount of repurchases are determined by our management based on a variety of factors such as the market price of our common stock, our corporate cash requirements, and overall market conditions. The Stock Repurchase Program is subject to applicable legal requirements, including federal and state securities laws and applicable Nasdaq rules. We may also repurchase shares of our Class A common stock pursuant to a trading plan meeting the requirements of Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, which would permit shares of our Class A common stock to be repurchased when we might otherwise be precluded from doing so by law.

The following table sets forth repurchase activity under the Stock Repurchase Program from inception through March 31, 2021:

Total number of

shares purchased

Average price

paid per share

Approximate

dollar value of

shares purchased

(in thousands)

March 2021

600,000

74.18

44,505

Total

600,000

44,505

As of March 31, 2021, we had remaining authorization to repurchase up to approximately $255.5 million of shares of our common stock under the Stock Repurchase Program.

Cash, Cash Equivalents and Restricted Cash

Our cash flows from operating, investing, and financing activities were as follows (in thousands):

	Three Months Ended March 31,
	2021			2020			Change
Net cash provided by (used in) operating activities	$	127,088		$	(38,607	)	$	165,695
Net cash used in investing activities		(19,781	)		(18,620	)		(1,161	)
Net cash (used in) provided by financing activities		(111,366	)		229,918			(341,284	)

Table of Contents

Cash Flows from Operating Activities

Cash flows provided by operating activities increased by $165.7 million during the three months ended March 31, 2021 compared to cash flows used in operating activities during the three months ended March 31, 2020. The increase is primarily due to higher cash-related net income and positive changes in operating assets and liabilities relative to the prior year period. Fluctuations in accounts receivable, unbilled services (including contract assets), and deferred revenue occur on a regular basis as we perform services, achieve milestones or other billing criteria, send invoices to customers, and collect outstanding accounts receivable. This activity varies by individual customer and contract. We attempt to negotiate payment terms that provide for payment of services prior to or soon after the provision of services, but the levels of accounts receivable, unbilled services (including contract assets), and deferred revenue can vary significantly from period to period.

Cash Flows from Investing Activities

For the three months ended March 31, 2021, we used $19.8 million in cash for investing activities, which consisted of $10.0 million of payments related to the acquisitions that were completed in the fourth quarter of 2020 and $11.2 million for purchases of property and equipment, partially offset by $1.4 million of proceeds from unconsolidated affiliates. We continue to closely monitor our capital expenditures, especially in light of the COVID-19 pandemic, while making strategic investments in the development of our information technology infrastructure to meet the needs of our workforce, enable efficiencies, reduce business continuity risks, and conform to changes in governing rules and regulations.

For the three months ended March 31, 2020, we used $18.6 million in cash for investing activities, which consisted of $11.9 million for purchases of property and equipment and $6.7 million for investments in unconsolidated affiliates.

Cash Flows from Financing Activities

For the three months ended March 31, 2021, we used $111.4 million in cash for financing activities, which consisted primarily of repayment of long-term debt, repurchases of our common stock, and payments related to tax withholdings for share-based compensation. These payments were partially offset by proceeds from our accounts receivable financing arrangement.

For the three months ended March 31, 2020, our financing activities provided $229.9 million in cash, which consisted primarily of a $300.0 million draw down of our Revolver, partially offset by repurchases of our common stock and contingent consideration payments.

Critical Accounting Policies and Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates, judgments, and assumptions that affect the reported amounts of assets, liabilities, revenues, and expenses during the period, as well as disclosures of contingent assets and liabilities at the date of the financial statements. We evaluate our estimates on an ongoing basis, including those related to revenue recognition, valuation of goodwill and identifiable intangibles, and tax-related contingencies and valuation allowances. These estimates are based on the information available to management at the time these estimates, judgments, and assumptions are made. Actual results may differ materially from these estimates. There have been no significant changes to our critical accounting policies and estimates. For additional information on all of our critical accounting policies and estimates, refer to Part II - Item 7 - Management’s Discussion and Analysis included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020.

Table of Contents

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

There have been no material changes to our quantitative and qualitative disclosures about market risk as compared to the quantitative and qualitative disclosures about market risk described in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020.

Item 4. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our CEO and CFO, has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on such evaluation, our CEO and CFO have concluded that as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.

In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives.

Changes in Internal Controls

There have been no changes in our internal control over financial reporting identified in management’s evaluation pursuant to Rules 13a-15(d) or 15d-15(d) of the Exchange Act during the period covered by this Quarterly Report on Form 10-Q that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II. OTHER INFORMATION

Item 1. Legal Proceedings.

We are party to legal proceedings incidental to our business. While our management currently believes the ultimate outcome of these proceedings, individually and in the aggregate, will not have a material adverse effect on our consolidated financial statements, litigation is subject to inherent uncertainties. Were an unfavorable ruling to occur, there exists the possibility of a material adverse impact on our financial condition and results of operations.

Please refer to “Note 16 – Commitments and Contingencies” of our unaudited condensed consolidated financial statements in Part I, Item 1 of this Quarterly Report on Form 10-Q for additional material developments to legal proceedings included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020.

Item 1A. Risk Factors.

There have been no material changes from the risk factors previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2020. Refer to “Risk Factors” in Part 1, Item 1A of that report for a detailed discussion of risk factors affecting us.

Item 2. Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchases of Equity Securities.

Recent Sales of Unregistered Securities

Not applicable.

Table of Contents

Purchases of Equity Securities by the Issuer

During the three months ended March 31, 2021, we repurchased 600,000 shares of our Class A common stock, $0.01 par value per share in a private transaction under our previously announced stock repurchase program described below, for a total purchase price of approximately $44.5 million, or $74.18 per share. As of March 31, 2021, we have remaining authorization to repurchase up to approximately $255.5 million of shares of our Class A common stock under the Stock Repurchase Program.

Period	Total number of shares purchased		Average price paid per share		Total number of shares purchased as part of publicly announced plans or programs (1)		Approximate dollar value of shares that may yet be purchased under the plans or programs (in thousands)
January 1, 2021 - January 31, 2021		—	$	—		—	$	300,000
February 1, 2021 - February 28, 2021		—	$	—		—	$	300,000
March 1, 2021 - March 31, 2021		600,000	$	74.18		600,000	$	255,495
		600,000				600,000

(1) On November 17, 2020, the Board authorized the repurchase of up to an aggregate of $300.0 million of our Class A common stock, par value $0.01 per share, to be executed from time to time in open market transactions effected through a broker at prevailing market prices, in block trades, or through privately negotiated transactions through December 31, 2022 (the “Stock Repurchase Program”). The Stock Repurchase Program took effect on January 1, 2021. Share repurchases are funded primarily with our working capital, cash flow from operations, and funds available through various borrowing arrangements. The Stock Repurchase Program does not obligate us to repurchase any particular amount of our Class A common stock, and may be modified, extended, suspended, or discontinued at any time. The timing and amount of repurchases are determined by our management based on a variety of factors such as the market price of our Class A common stock, our corporate cash requirements, and overall market conditions. The Stock Repurchase Program is subject to applicable legal requirements, including federal and state securities laws and applicable Nasdaq rules. We may also repurchase shares of our Class A common stock pursuant to a trading plan meeting the requirements of Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, which would permit shares of our Class A common stock to be repurchased when we might otherwise be precluded from doing so by law.

We immediately retired all of the repurchased common stock and charged the par value of the shares to common stock. The excess of the repurchase price over the par value was applied on a pro rata basis against additional paid-in capital, with the remainder applied to accumulated deficit.

Item 5. Other Information.

Not applicable.

Table of Contents

Item 6. Exhibits


		Incorporated by Reference (Unless Otherwise Indicated)
Exhibit Number	Exhibit Description	Form	File No.	Exhibit	Filing Date
10.1	Fifth Amendment to the Purchase and Sale Agreement, dated as of January 22, 2021, among each of the entities listed on the signature pages hereto as an Originator, Syneos Health, LLC, as services, and Syneos Health Receivables LLC.	10-K	001-36730	10.16.5	February 18, 2021
10.2	Tenth Amendment to the Receivables Financing Agreement, dated as of January 22, 2021, by and among Syneos Health Receivables LLC, as borrower, Syneos Health, LLC, as initial services, Regions Bank, as a lender, and PNC Bank, National Association, as administrative agent and as a lender.	10-K	001-36730	10.17.11	February 18, 2021
10.3	Share Repurchase Agreement, dated February 26, 2021, by and among Syneos Health, Inc. and certain selling stockholders named therein.	8-K	001-36730	10.1	March 3, 2021
10.4	Form of Global Performance Restricted Stock Unit Award Agreement under Syneos Health, Inc. 2018 Equity Incentive Plan (U.S. Participants).	8-K	001-36730	10.1	January 21, 2021
10.5	Form of Global Performance Restricted Stock Unit Award Agreement under Syneos Health, Inc. 2018 Equity Incentive Plan (Non-U.S. Participants).	8-K	001-36730	10.2	January 21, 2021
31.1	Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.	—	—	—	Filed herewith
31.2	Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.	—	—	—	Filed herewith
32.1	Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.	—	—	—	Furnished herewith
32.2	Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.	—	—	—	Furnished herewith
101.INS	Inline XBRL Instance Document - the Instance Document does not appear in the interactive data file because its XBRL tags are embedded within the Inline XBRL document.	—	—	—	Filed herewith
101.SCH	Inline XBRL Taxonomy Extension Schema Document.	—	—	—	Filed herewith
101.CAL	Inline XBRL Taxonomy Extension Calculation Linkbase Document.	—	—	—	Filed herewith
101.DEF	Inline XBRL Taxonomy Extension Definition Linkbase Document.	—	—	—	Filed herewith
101.LAB	Inline XBRL Taxonomy Extension Label Linkbase Document.	—	—	—	Filed herewith
101.PRE	Inline Taxonomy Extension Presentation Linkbase Document.	—	—	—	Filed herewith
104	Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).	—	—	—	Filed herewith

Table of Contents

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		SYNEOS HEALTH, INC.


Date: April 28, 2021	BY:	/s/ *Jason Meggs*
		Jason Meggs
		Chief Financial Officer (Principal Financial Officer)

Dates Referenced Herein and Documents Incorporated by Reference

This ‘10-Q’ Filing	Date	Other Filings

	8/1/24
	3/26/24
	1/15/24
	7/15/23
	3/31/23
	12/31/22
	10/3/22
	12/31/21	10-K
	6/30/21	10-Q, 4, 8-K
Filed as of:	4/29/21	8-K
Filed on:	4/28/21	8-K
	4/26/21
For Period end:	3/31/21	4, DEF 14A, DEFA14A
	3/3/21	4, 424B7, 8-K
	3/1/21	FWP
	2/28/21
	2/18/21	10-K, 4, 8-K
	2/1/21	4, CORRESP, SC 13G/A
	1/31/21
	1/28/21
	1/21/21	8-K, 8-K/A
	1/1/21
	12/31/20	10-K
	12/17/20
	12/9/20
	11/24/20	4, 8-K
	11/17/20	4, 8-K
	10/30/20
	10/2/20
	9/4/20
	8/7/20
	3/31/20	10-Q
	3/11/20
	9/26/19
	12/31/18	10-K, NT 10-K
	12/5/18
	11/21/18
	9/20/18
	7/30/18	4
	7/23/18
	6/7/18
	5/29/18	4
	3/30/18
	1/30/18	4
	1/25/18	SC 13G/A
	12/1/17	8-K
	11/9/17	10-Q, 8-K
	11/8/17	8-K
	5/10/17	10-Q, 8-K, DEFA14A
		List all Filings

2 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 6/04/21  Syneos Health, Inc.               424B7                  1:390K                                   Donnelley … Solutions/FA
 5/05/21  Syneos Health, Inc.               424B7                  1:398K                                   Donnelley … Solutions/FA

3 Previous Filings that this Filing References

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 3/03/21  Syneos Health, Inc.               8-K:1,5,9   2/26/21   13:480K                                   Donnelley … Solutions/FA
 2/18/21  Syneos Health, Inc.               10-K       12/31/20  130:23M                                    ActiveDisclosure/FA
 1/21/21  Syneos Health, Inc.               8-K:5,9     1/14/21   12:948K                                   ActiveDisclosure/FA

↑Top

Filing Submission 0001564590-21-021455 – Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Syneos Health, Inc. – ‘10-Q’ for 3/31/21

On: Wednesday, 4/28/21, at 5:42pm ET · As of: 4/29/21 · For: 3/31/21 · Accession #: 1564590-21-21455 · File #: 1-36730

Quarterly Report — Form 10-QFiling Table of Contents

‘10-Q’ — Quarterly ReportDocument Table of Contents

This is an HTML Document rendered as filed. [ Alternative Formats ]

Dates Referenced Herein and Documents Incorporated by Reference

2 Subsequent Filings that Reference this Filing

3 Previous Filings that this Filing References

Quarterly Report — Form 10-Q
Filing Table of Contents

‘10-Q’ — Quarterly Report
Document Table of Contents